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Abstract 
 
N-Acetylneuraminic acid synthase (NANAS) is an enzyme responsible for the biosynthesis of 
N-acetylneuraminic acid (NANA). NANA is the most common form of a group of nine carbon 
sugar molecules called the sialic acids. NANA production is common in mammalian cells for 
vital physiological processes. A few species of microorganisms, including pathogenic 
bacteria such as Neisseria meningitidis and Campylobacter jejuni, are known to synthesise 
NANA by their bacterial NANAS. These pathogenic bacteria synthesise NANA for molecular 
mimicry, allowing them to evade the host immune system. 
This thesis examines the NANAS enzymes from N. meningitidis and C. jejuni. Inhibitory 
studies with these enzymes were explored by performing enzyme kinetics with substrate 
analogues and a product analogue which structurally mimic the natural substrates or 
product of NANAS. Inhibition constants were determined for a variety of analogues to give 
insight in to how the enzyme accommodates its substrates within the active site of NANAS. 
This study may be a useful step in the development of alternative antibiotics for bacterial 
meningitis and other diseases in the future. 
NANAS catalyses a condensation reaction between phosphoenolpyruvate (PEP) and N-acetyl 
mannosamine (ManNAc). Both PEP and ManNAc analogues were explored as inhibitors of 
the enzymes. Results from this study show that increasing steric bulk of the substituents at 
C3 of PEP unexpectedly delivers more potent inhibition of the enzyme. This finding suggests 
that a slightly modified binding position of the PEP analogue within the PEP binding site of 
the enzyme may be responsible for the inhibition. A reduced acyclic analogue of ManNAc 
was found to be an effective inhibitor of the enzymes. This finding indicates how important 
the acyclic form of ManNAc is in the reaction mechanism catalysed by this enzyme. 
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Chapter 1                                                                                                             
Background information 
1.1 Introduction 
Sialic acids are a group of nine carbon α-ketoacid molecules of which N-acetylneuraminic 
acid (NANA) is the most common. Sialic acids play many important physiological roles in 
mammalian systems.1,2 The aim of this research is to study the inhibition of the enzyme 
responsible for the synthesis of NANA, bacterial N-acetylneuraminic acid synthase (NANAS) 
from both Neisseria meningitidis (NmeNANAS) and Campylobacter jejuni (CjeNANAS). 
NANAS catalyses the reaction between phosphoenol pyruvate (PEP) and N-
acetylmannosamine (ManNAc) to form NANA and inorganic phosphate (Pi) (Figure 1.1).3 
 
  
Figure 1.1 Biosynthesis of NANA. 
 
NANA is synthesised using slightly different biosynthetic routes in mammals and bacteria. 
Mammalian biosynthesis of NANA requires two extra enzymatic steps which involve the 
phosphorylation of ManNAc into N-acetyl mannosamine 9-phosphate (ManNAc-6-P) 
followed by the dephosphorylation of the synthesised product (Figure 1.2).  
 
 2 
 
  
Figure 1.2 Difference between bacterial and mammalian NANAS biosynthesis. (A) Shows bacterial 
biosynthesis of NANA. (B) Shows the mammalian biosynthesis of N-acetylneuraminic acid 9-
phosphate (NANA-9-P) by the catalytic reaction of mammalian N-acetylneuraminic acid 9-phosphate 
synthase (NANA-9-PS). 
 
This difference between mammalian and bacterial metabolism makes NANAS a possible 
target for antibacterial drug discovery.  By elucidating and developing potent inhibitors for 
this enzyme, new and possibly more effective antibiotics against pathogenic bacteria may 
be discovered. This is of specific importance given the emergence of multi-drug resistant 
meningitis strains, and other pathogenic organisms.4 
1.2 The sialic acid synthase family 
Sialic acid synthases are a group of enzymes which produce sialic acids. There are different 
sialic acid synthases, each responsible for the biosynthesis of different sialic acids. For 
example, pseudaminic acid synthase (PseS) and N,N-diacetyllegionaminic acid synthase 
(LegS) catalyse the condensation of PEP with 2,4-diacetamido-2,4,6-trideoxy-β-L-
altropyranose and 2,4-diacetamido-2,4,6-trideoxy-D-mannopyranose respectively (Figure 
1.3).5,6 
 3 
 
 
Figure 1.3 Catalytic reaction of pseudaminic acid synthase (PseS) and legionaminic acid synthase 
(LegS)  (A) Shows the reaction catalysed by PseS, producing psedaminic acid and (B) details the 
reaction catalysed by LegS which produces legionaminic acid. 
 
1.3 Sialic acids and N-acetylneuraminic acid (NANA)  
1.3.1 Characteristics of sialic acids 
Sialic acids are a group of diverse sugar molecules which have an α-keto acid functional 
group on a nine carbon backbone.1 The diversity is due to the fact that these molecules have 
large variety of modifications,1,7 ranging from the esterification of the hydroxyl groups at 
C7,C8 and C9 positions with acetic acid, to the addition of another functional group such as 
a lactoyl group at C9 and a methyl, or sulphate group at the C8 position (Figure 1.4).8 
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Figure 1.4 Sialic acid diversity.1 
 
The enzyme of interest for this study produces the specific sialic acid NANA. This type of 
sialic acid is the most common type in mammals, including humans, and NANA has an N-
acetyl functional group at the C5 position.1,2 NANA is so common that the term sialic acid is 
often used synonymously with NANA. 
Other significant forms of sialic acid include; neuraminic acid, N-glycolylneuraminic acid and 
2-keto-3-deoxy-glycero-galacto-nonulosonic acid (KDN) (Figure 1.5) which are all closely 
related to NANA.2,9 Neuraminic acid is an unmodified form of sialic acid that lacks the C5 
acetyl group; this form of sialic acid rarely exists in nature.8 N-Glycolylneuraminic acids have 
an N-glycolyl functional group instead of the N-acetyl functional group, which is formed 
from an oxidation of the acetyl group in the cytosol of the cell during biosynthesis.9 This 
form of sialic acid is also common in mammals except for humans due to an irreversible 
mutation to the human gene responsible for the N-glycolylneuraminic acid synthesis.10 KDN 
is considered unusual because of its deaminated form.11 
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Figure 1.5 Examples of sialic acid structures: A) Neuraminic acid; B) N-acetylneuraminc acid; C) N-
glycolneraminic acid; D) 2-keto-3-deoxy-glycero-galacto-nonulosonic acid (KDN). 
 
1.3.2 Physiological roles in mammals 
In biological systems, sialic acids are expressed on the very outer periphery of glycoproteins 
or glycolipids which act as “surface markers” as they are known to interact with various cells 
and physiological agents.8,12 The diverse nature of sialic acids gives an overwhelming variety 
to the characteristics of glycoproteins and glycolipids, particularly glycans, thereby sialic 
acids play a crucial role in intercellular processes such as cell recognition, physiological 
development, and cell adhesion.13 This makes sialic acids essential for normal physiological 
processes in multicellular organism including mammals.14  
Sialic acids participate in various recognition processes by expressing themselves as 
“patterns”, allowing the immune system to distinguish between their host and foreign or 
invading structures.15  
For physiological development and cell adhesion, sialic acids have roles in the brain, or more 
specifically, on the outer surface of the neural cell adhesion molecules, which is another 
type of protein responsible for the adhesion of adjacent neurons.16 Sialic acids can be 
expressed as repetitive chains of polysialic acids, which have an overall negative charge that 
prevents the cross linking of neural cell adhesion molecules by electronegative repulsion. 
The presence of polysialic acids in the intercellular spaces of neurons (on the cell adhesion 
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molecules) prevents other neurons from collapsing together allowing the neurons to have 
just enough space to function properly.17 
Sialic acids have structural and protective roles in mucins (proteins which makes up the 
mucus), providing the repulsive electronegative forces acting between their negative 
charges. This allows the trapping of water molecules on the surface of mucins via hydrogen 
bonds, giving mucus its slimy and protective properties.8 
Since sialic acids play vital roles in metabolism, there are diseases associated with sialic acid 
expression. For example, tumour cells over express sialic acids in a form of glycoconjugates 
or polysialic acids on the cell surface.18,19 The overall negative charge of sialic acid 
glycocojugates and polysialic acids on the tumour cell surface gives an electronegative 
repulsion between other cells, causing cancerous cells to lose cell adhesion to the tumour 
mass, aiding their pathology by proliferation across the body.18,20 Conversely, the disruption 
of sialic acid biosynthesis caused by irreversible mutations can result in severe form of 
proteinuria (excessive urinary protein excretion) or neuromuscular disorders.21,22 
1.3.3 The role of NANA in bacteria 
There are at least two ways by which bacteria utilise NANA. Firstly, some bacteria use NANA 
as an alternative source of energy, in a catabolic pathway that ultimately produces fructose. 
Secondly, and most interestingly, some bacteria use NANA for the purpose of 
camouflage.23,24   
Despite their diverse nature, the biosynthesis of sialic acids is not ubiquitous.7 While the 
expression of sialic acids is common in mammalian cells, only certain species of 
microorganisms can synthesise and express NANA on their cell surface.25 Such 
microorganisms include Neisseria meningitidis and Campylobacter jejuni as these bacteria 
utilise NANA for a clever survival strategy in a form of molecular mimicry.23 N. meningitidis is 
often associated with meningitis26 and other diseases such as meningococcemia,27 a type of 
blood poisoning. C. jejuni is responsible for gastroenteritis, often associated with food-borne 
illness, and in the worst cases C. jejuni can cause paralysis in the form of Guillain-Barre 
syndrome.28 These pathogenic bacteria coat themselves with sialic acids, so that the host 
immune system cannot readily tell the difference between the bacteria and their own cells 
to avoid being attacked by the immune system.29  
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1.4 The enzyme, NANAS 
1.4.1 General enzyme structure 
The structure of NANAS isolated from NmeNANAS has been previously determined.3,9 The 
structure of NmeNANAS is a domain swapped homodimer (Figure 1.6)9, consisting of two 
identical monomeric units. Each subunit comprises two distinct domains joined together by 
an extended linker region.9  
 
 
Figure 1.6 Quaternary structure (a domain swapped homodimer) is made up of two identical 
monomers/subunits. One monomer is shown in colour and the other identical monomer in grey. The 
monomeric unit consists of a TIM barrel fold (red) and an anti-freeze protein like domain (blue) 
connected by a linker region (orange) (PDB code 1XUZ). 
 
The N-terminal region of the subunit is a TIM (β/α)8 barrel which has eight β strands forming 
a β-barrel enclosed by eight α helices.9 The C-terminal region has a novel structure similar to 
that of functional type III antifreeze protein.3 The interaction of the two subunits, includes 
the close packing between two ends of the C-terminus from the opposing TIM barrel, the 
packing of the extended linker region between one monomer with an opposing TIM barrel 
from the second monomer, and then the interaction between the N-terminal region 
antifreeze-like domain from one monomer with the opposing TIM barrel of the second 
monomer.3  
Anti-freeze protein like 
domain 
Linker 
(β/α)8 barrel fold 
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1.4.2 Active site and key amino acid residues 
The active site of the enzyme (Figure 1.7) is located at the C–terminal end of the TIM barrel 
domain.3 The antifreeze domain contributes three residues into the catalytic site of the 
opposing monomer barrel. These three amino acid residues, Thr-285, Phe-288, and Arg-314, 
are involved in substrate binding.3 Arg-314 is highly conserved suggesting it is likely that Arg-
314 serves a specific role in the functionality of the enzyme. X-ray crystallography of 
NmeNANAS with PEP and N-acetylmannosaminitol (an unreactive, reduced form of 
ManNAc) bound, shows hydrogen bonding between Arg-314 and the carbonyl oxygen of N-
acetylmannosamine. With this evidence it is proposed that the residue Arg-314 forms a 
hydrogen bond with the acetyl oxygen of the substrate ManNAc.30 A previous study 
involving the substitutions of Arg-314 into either Lys or Ala suggested that Arg-314 is not 
necessary for binding, but rather for steering the ManNAc into a reactive position.30  
The Arg-314-Lys variant had diminished catalytic activity, whereas the Ala substitution was 
non-functional. According to modelling studies, both variants accommodate the substrate 
ManNAc in the active site. The study proposed that the guanidinium functionality of Arg-314 
is not essential for the ability to bind ManNAc but is required for orientating ManNAc into a 
correct position within the active site, in order to react with PEP.30 
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Figure 1.7 The active site of NmeNANAS. Arg-314’ contributed by the other monomer is coloured as 
grey, Mn2+ as a pink sphere, PEP as blue with phosphate group shown as orange, and N-
acetylmannosaminitol as green (rManNAc). The residues coloured red represent the amino acid 
residues from the TIM barrel fold. The cyan spheres represent water molecules. (PDB code 1XUZ). 
 
1.5 Biosynthesis of NANA 
1.5.1 Metabolic pathway for NANA synthesis  
The bacterial pathway for NANA biosynthesis is distinct from that of mammals (Figure 1.8). 
In bacterial systems, NANA is synthesised by the enzyme NANAS, utilising the substrate PEP 
and ManNAc formed from another separate enzyme, UDP-N-acetylglucosamine epimerase.2 
Conversely, animals produce NANA by first phosphorylating ManNAc using ATP, in a 
reaction catalysed by ManNAc kinase to form N-acetylmannosamine 6-phosphate (ManNAc-
6-P) and ADP.2,13 ManNAc-6-P then undergoes a condensation reaction with PEP, catalysed 
by the mammalian enzyme N-acetylneuraminic-9-phosphate synthase (NANA-9-PS), to form 
N-acetylneuraminic acid 9-phosphate (NANA-9-P).2 This phosphorylated version of NANA 
then undergoes dephosphorylation by the action of the enzyme NANA-9-P phosphatase to 
form NANA.2 Finally NANA, formed in both mammalian and bacterial pathways, is activated 
by the action of the enzyme CMP-NANA synthetase, utilising cytosine triphosphate (CTP).2 
rManNAc 
PEP 
Mn2+ 
Arg-314’ 
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This enzyme produces CMP-NANA (the activated form of NANA)2 which is used to assimilate 
NANA into functional glycoproteins and glycolipids via endoplasmic reticulum–golgi 
apparatus pathways.15,25  
 
  
Figure 1.8 The bacterial and mammalian pathway for NANA synthesis. 
 
The use of CTP to activate NANA is considered biologically unusual, since most other 
monosaccharides  are activated in the form of uridine or guanine (UDP or GDP) in 
vertebrates.7 Sialic acid or NANA is also known to be an alternative source of energy via 
catabolic processes in some species of bacteria.23,31  
These two different enzymatic pathways between mammals and bacteria allow the 
development of selective inhibitory compounds against bacterial NANAS. Inhibitors can be 
derived from PEP and ManNAc analogues as these substrate analogues can mimic the 
natural substrates of the enzyme. The results of inhibition studies may aid in the further 
design of specific drugs. 
1.5.2 Reaction mechanism of NmeNANAS 
NANAS catalyses the condensation reaction between the substrates, PEP and ManNAc, 
whereas the mammalian enzyme utilises ManNAc-6-P (mannosamine-6-phosphate). NANAS 
is a divalent metal ion dependent enzyme, and Mn2+-bound enzyme displays the highest 
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catalytic activity. Two possible mechanisms for the catalytic action of the enzyme were 
proposed since there are two potential ways PEP can react with the aldehyde functional 
group of ManNAc.9 
The first possible mechanism would occur via the cleavage of the O-P bond of PEP (Figure 
1.9). This mechanism begins with the nucleophilic attack by a water molecule on the 
phosphorus, releasing phosphate and a pyruvate in a form of an enolate. This enolate 
subsequently attacks the carbonyl functional group of ManNAc, finally producing the 
product NANA in a linear form.  
 
Figure 1.9 Possible reaction mechanism of NANAS via P-O cleavage. 
 
The second possible mechanism begins with the carbonyl carbon of ManNAc undergoing 
nucleophilic attack by the C3 carbon of the PEP molecule forming an oxocarbenium ion 
intermediate (Figure 1.10).9 
 
Figure 1.10 Possible reaction mechanism of NANAS via C-O bond cleavage. 
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The intermediate is then readily attacked by a water molecule to produce a tetrahedral 
intermediate.3,9 The tetrahedral intermediate will then subsequently lose the phosphate 
group, which means that this reaction mechanism operates via cleavage of a C-O bond of 
PEP.3 This mechanism also results in the formation of NANA as the ring opened form.  
Isotopic labelling of oxygen was used to determine which of the two proposed mechanisms 
for the reaction catalysed by NANA was likely to be operating.9 18O was incorporated into 
the phosphate group of the substrate, PEP. The use of this labelled PEP determined which 
mechanism occurred by examination of the products. If the reaction occurred via the P-O 
bond cleavage of PEP (the first mechanism), the 18O label will be incorporated into the 
product, NANA. If the reaction proceeds via the C-O bond cleavage of PEP (the second 
mechanism) then the 18O label will remain in the inorganic bi-product of phosphate. 31P 
NMR spectroscopy was used to observe the reaction between 18O incorporated PEP and 
ManNAc with NmeNANAS.2,9 The upfield shift of resonance arising from the phosphorus 
bonded to the 18O showed that the oxygen isotope was incorporated into the inorganic 
phosphate and not into the product NANA which is consistent with C-O bond cleavage 
(Figure 1.11).2,9 This type of reaction is considered unusual because few other PEP utilising 
enzymes are known to proceed by C-O bond cleavage. Such enzymes that share this 
mechanism may be related by evolution and will be discussed in detail below. 
 
Figure 1.11 Proposed reaction mechanism of NANA synthesis. 
 
The stereospecificity of the reaction has also been studied in other experiments using 1H 
NMR spectroscopic analysis with CjeNANAS.29  When the enzyme catalysed the reaction 
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with Z-[3-2H]-PEP, the enzyme produced (3S)-3-deutero-NANA (2H on the equatorial 
position), whereas E-[3-2H]-PEP produces (3R)-3-deutero-NANA (2H on the axial position) 
(Figure 1.12).29 When E-[3-F]-PEP was used during a 19F NMR spectroscopic analysis, the 
enzyme did not accept this compound as an alternative substrate.  Z-[3-F]-PEP on the other 
hand was accepted and formed (3S)-3-fluoro-NANA. These observations show that only the 
si face of the substrate PEP reacts with the si face of the carbonyl group of ManNAc.29  
 
Figure 1.12 The investigation of the stereochemistry of NANAS reaction, (A) shows the NANAS 
catalysed reaction with Z-[3-2H]PEP which forms (3S)-3-deutero-NeuNAc. (B) Shows the reaction 
with E-[3-2H]PEP which gives (3R)-3-deutero-NeuNAc. Deuterium, 2H, is coloured red. 
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1.5.3 Metal dependency 
All NANAS require a divalent metal ion to function.9 Within the active site there are two key 
amino acid residues, His-215 and His-236 which coordinate to the divalent metal ion (Figure 
1.13).3 The divalent metal ion also coordinates with two water molecules, the carbonyl 
oxygen of the substrate ManNAc and the oxygen from the phosphate group of PEP giving an 
octahedral coordination geometry.3 
 
Figure 1.13 Divalent metal coordination within the active site of NANAS. 
 
The Mn2+ ion gives the highest catalytic activity for NmeNANAS.3,9 Other divalent metal ions 
are also known to activate the NANAS such as Co2+ and Mg2+ ions, where Mn2+ 
closelyfollowed by Co2+  both provide the highest catalytic activity for NmeNANAS and 
CjeNANAS.9,29 In contrast the human NANAPS showed the highest catalytic activity for 
Mg2+.32 
The divalent metal ion coordinates to the carbonyl oxygen of the substrate ManNAc which 
activates the carbonyl group making ManNAc more susceptible to nucleophilic attack.3,9 
1.5.4 Intermediates of NANAS reaction 
Two intermediates are predicted to be part of the reaction: oxocarbenium intermediate and 
the tetrahedral intermediate, formed by the attack of water on the oxocarbenium ion 
(Figure 1.14).  
His-236 
His-215 PEP 
ManNAC 
Mn2+ 
Waterax 
Watereq 
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Figure 1.14 The intermediates of NANAS catalytic reaction. 
 
The design of inhibitors, based on the structural mimicry of these intermediates has been 
carried out in past studies. Analogues of the high energy intermediates may be a useful 
strategy for disrupting the catalytic function of NANAS.  
1.5.4.1 Inhibition of NANAS with a tetrahedral intermediate mimic. 
An analogue which structurally mimics the tetrahedral intermediate was synthesised and 
tested on NmeNANAS reporting a potent inhibition constant of 3.1 ± 0.1 µM (Figure 1.15).3 
 
 
Figure 1.15 Tetrahedral intermediate mimicking inhibitor. 
 
The hydroxyl group bonded to the C2 position were replaced in the inhibitor by a hydrogen 
atom.  
In this study, NANAS was tested with two diastereoisomers of the inhibitor, which bears 
either (2R) or a (2S)-configuration at the tetrahedral centre. Inhibition studies using these 
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stereoisomers demonstrated that the (2R)-configuration exhibited a stronger inhibition 
constant than the compound with the (2S)-configuration. An X-ray crystallographic structure 
of NmeNANAS-inhibitor complex, showed the (2R) stereoisomer of the tetrahedral 
intermediate analogue bound in the active site. This suggests that the tetrahedral 
intermediate also bears the (2R)-configuration, formed from the water molecule attacking 
the si face of the oxocarbenium intermediate, during NANA biosynthesis.3 
An oxocarbenium intermediate-mimicking analogue was tested on an enzyme which is 
related to NANAS. The study which uses this analogue will be explained in later sections of 
this chapter in detail.  
1.6 Related Enzymes 
Since NANAS catalyses a reaction via the unusual C-O bond cleavage of PEP, it is thought 
that other PEP utilising enzymes which cleave this C-O bond may be evolutionarily related.2 
There are only a few known enzymes which catalyse a similar reaction, but one particular 
category of enzyme are of interest (which includes NANAS), is the PEP aldolases. Such 
enzymes include 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase (DAH7PS) and 3-
deoxy-D-manno-octulosonate 8-phosphate synthase (KDO8PS) which both catalyse the 
addition of PEP to an aldehyde in an aldol condensation-like reaction, similar the mechanism 
used by NANAS.33,34 Despite low sequence identity, NANAS, DAH7PS, and KDO8PS share 
structural similarities as these enzymes all share a TIM (βα)8 barrel fold.
35,36  
The reaction mechanism occurring via C-O bond cleavage has been studied in both DAH7PS 
and KDO8PS. Both enzymes have also have been the subject of extensive inhibition studies 
with a variety of substrate analogues.36-38 
1.6.1 Introduction to DAH7PS  
DAH7PS catalyses the formation of 3-deoxy-D-arabino-heptulosonate 7-phosphate (DAH7P) 
from the substrates PEP and D-erythrose 4-phosphate (E4P), with the release of inorganic 
phosphate (Figure 1.16).39,40  
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Figure 1.16 Reaction catalysed by DAH7PS. 
 
DAH7PS is an important enzyme involved in the first step of the shikimate pathway, the 
metabolic pathway ultimately responsible for the biosynthesis of aromatic compounds.41 
The pathway not only synthesises the aromatic amino acids, phenylalanine, tyrosine and 
tryptophan, but also a number of other important aromatic compounds such as 
siderophores and quinone.42 The shikimate pathway operates in plants, fungi and bacteria 
but is absent in mammals, which allows the development of herbicides, fungicides and 
antibiotics which target this pathway however do not affect mammals.41,42  
The enzymatic mechanism of DAH7PS is similar to that of the related enzyme NANAS (Figure 
1.17). DAH7PS catalyses the reaction between PEP and E4P by reacting PEP with the 
aldehyde of E4P in an aldol-addition like fashion. The enzymatic reaction proceeds via 
cleavage of the C-O bond.43  
 
  
Figure 1.17 Proposed mechanism for DAH7PS. 
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One significant difference between the reaction mechanism of DAH7PS and NANAS is the 
stereospecificity of the reaction (Figure 1.18). For DAH7PS, PEP attacks the re face of the 
aldehyde.44 This leads to altered styereochemistry at C4 of the product. In addition, it also 
has been proposed that the water attacks the oxocarbenium ion intermediate from the re 
face. This would result in a tetrahedral intermediate with the opposite configuration at C2 
to that in the NANAS reaction.35 
 
 
Figure 1.18 The si face of PEP attacks the re face of aldehyde during the reaction catalysed by the 
enzyme, DAH7PS. 
 
1.6.1.2 Inhibition of DAH7PS with oxocarbenium mimic. 
Past studies used analogues which mimic the structure of the oxocarbenium intermediate 
for the reaction catalysed by DAH7PS and showed great success in exhibiting potent 
inhibition.42 
The oxocarbenium ion intermediate possesses a partial double bond between the C2 
position of PEP structure and the bridging phosphate (Figure 1.19). This characteristic was 
taken advantage of by designing analogues which mimic the planar structure of the 
oxocarbenium ion intermediate.  
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Figure 1.19 Resonance of the oxocarbenium ion. 
 
The intermediate mimicking analogue tested against DAH7PS is vinyl phosphonate (Figure 
1.20). This analogue has a planar double bond at C2, mimicking the planar geometry of the 
oxocarbenium intermediate.  
Vinylphosphonate has a phosphate group replaced by a methyl phosphono group, 
effectively replacing an oxygen atom bonded to C2 with a methylene group. The strong C-P 
bond prevents any catalytic reaction in the active site. The inhibition constant for vinyl 
phosphonate against DAH7PS was determined to be 4.7 ± 0.7 µM. 
 
  
Figure 1.20 Vinyl phosphonate and the oxocarbenium intermediate. 
 
1.6.2 Introduction to KDO8PS 
KDO8PS utilises the substrate PEP and arabinose 5-phosphate (A5P) to synthesise 3-deoxy-
D-manno-octulosonate 8-phosphate (KDO8P) with the release of phosphate (Figure 1.21).45  
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Figure 1.21 Reaction catalysed by KDO8PS. 
 
KDO8PS is a key enzyme involved in the biosynthetic pathway of lipopolysaccharide 
synthesis in Gram-negative bacteria.46 Lipopolysaccharides are used by bacteria to create a 
strong outer layer to their cell which gives the bacteria cell structural integrity.  
As with DAH7PS, the enzymatic mechanism of KDO8PS is similar to that of the related 
enzyme NANAS (Figure 1.22). KDO8PS catalyses the reaction between PEP and E4P by 
reacting PEP with the aldehyde of A5P in an aldol reaction. As for NANAS, the enzymatic 
reaction also proceeds via the cleavage of the C-O bond.  
 
Figure 1.22 Proposed reaction mechanism of KDO8PS. 
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As for DAH7PS, PEP attacks the re face of the aldehyde (Figure 1.23).47  
 
Figure 1.23 The si face of PEP attacks the re face of aldehyde during the reaction catalysed by the 
enzyme, KDO8PS. 
 
1.7 Aims of this thesis 
The aim of this research was to investigate and compare the inhibition of NANAS enzymes 
from two different species, N. meningitidis and C. jejuni, with inhibitors derived from 
substrate analogues. 
In order to achieve this, kinetic assays were performed on NmeNANAS or CjeNANAS with 
their natural substrates (PEP and ManNAc) in presence of a variety of analogues.  
Chapter two describes the studies with analogues of PEP. Chapter three outlines the studies 
with a ManNAc and a NANA analogue.  
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Chapter 2                                                                                                      
Preparation of the enzyme NANAS and kinetic 
assays with PEP analogues 
2.1 Introduction 
The goal of this research was to test various substrate and product analogues on wild-type 
NmeNANAS and CjeNANAS. In order to undertake this work both NmeNANAS and CjeNANAS 
had to be obtained by protein expression and purification. For both enzymes, the genes 
encoding the proteins had been cloned and inserted into an expression plasmid prior to the 
commencement of this work.30 
This chapter describes a series of experiments in which a range of PEP analogues were 
tested as alternative substrates and inhibitors for NANAS. 
2.2 Preparation of the enzyme, NmeNANAS and CjeNANAS 
2.2.1 Wild-type NmeNANAS and CjeNANAS expression in general 
The pDEST™17 vectors bearing either the NeuB or Cj1141 genes (encoding wild-type 
NmeNANAS or CjeNANAS respectively) were transformed into E. coli BL21 (DE3) pBB540 for 
expression and purification. The vector pDEST™17 also encodes an N-terminal His-tag to 
allow for purification of the protein by immobilised metal affinity chromatography (IMAC). A 
tobacco etch virus protease (TEV) cleavage sequence was also incorporated between the 
NmeNANAS or CjeNANAS gene and the His-tag sequence to allow for tag removal after 
purification. Protein expression was induced through the addition of isopropyl β-D-1-
thiogalactopyranoside (IPTG), which binds to the lac operon site incorporated into the 
vector. 
2.2.2 Growing cells producing NANAS 
The cell lines bearing the plasmids for the expression of the two NANAS enzymes were 
grown and harvested by centrifugation.  
The general protocol that was used for obtaining purified enzymes is shown in Figure 2.1. 
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Figure 2.1 Flow diagram of protein purification in general. 
 
2.2.3 Obtaining supernatant by cell lysis and centrifugation 
Cells were lysed by sonication following their re-suspension in buffer solution. The resulting 
lysate was clarified by centrifugation allowing removal of the cell debris. Both NmeNANAS 
and CjeNANAS are soluble so large proportions of the over-expressed protein were 
observed in the supernatant after centrifugation in both cases.  
2.2.4 Immobilised metal affinity chromatography (IMAC) 
The NANAS enzymes were isolated from the supernatant using IMAC. The IMAC column 
used for this procedure was charged with Co2+ ions to allow binding of the His-tag 
incorporated at the N-terminal of both NANAS enzymes. This enabled the NANAS enzymes 
to be selectively separated from other background E. coli proteins. The proteins bound to 
the IMAC column were eluted using buffer containing high concentrations of imidazole. The 
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fractions containing NANAS were pooled together and subsequently run through a desalting 
column.  
2.2.5 Desalting column and TEV cleavage 
Following IMAC, each protein was desalted to remove the imidazole. The fractions that 
eluted from the desalting column were pooled together and treated with TEV protease. The 
TEV reaction was carried out overnight at 4°C as NANAS is known to be temperature 
sensitive.  TEV recognises the protein cleavage sequence (Figure 2.2) engineered between 
the His-tag and NANAS sequences.  
 
SYYHHHHHHSGGQFYLNESGSGM 
Figure 2.2 The His-tag sequence located at the N-terminus of the protein sequence from the vector, 
pDEST™17. In red is the polyhistidine tag which coordinates to a metal ion, and in yellow is the 
protein sequence recognised by TEV protease. The His-tag is cleaved by TEV protease between 
glycine and glutamine residues. 
 
The TEV protease was expressed with its own noncleavable His-tag. The protein with the 
His-tag cleaved was therefore separated from both the TEV protease and the cleaved His-
tags using a second IMAC step. Any other impurities that may have been eluted from the 
first IMAC step will be removed in this second IMAC procedure along with TEV and cleaved 
His-tag. Finally, the fractions containing NANAS were purified by size exclusion 
chromatography (SEC). 
2.2.6 Size-exclusion chromatography  
The pooled fractions of His-tag cleaved NANAS were eluted through a SEC column in order 
to purify the protein further. The eluted protein was collected as fractions, pooled together 
and concentrated. The purified NmeNANAS or CjeNANAS were flash frozen in the SEC buffer 
and stored at -80 °C until required for experimentation.  
Site of cleavage 
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The procedure of protein purification and the purity of the final products were checked 
using gel electrophoresis. The molecular weight of NmeNANAS and CjeNANAS is 38.34 kDa 
and 38.48 kDa respectively shown in Figures 2.3 and 2.4 respectively.  
 
 
Figure 2.3 SDS-PAGE gel showing purification steps of NmeNANAS (1 whole lysed cells, 2 
supernatant, 3 insoluble protein, 4 IMAC bound protein, 5 IMAC flowthrough, 6 Desalt and TEV 
protease, 7 IMAC bound, 8 IMAC flow through, 9 SEC). 
 
 
Figure 2.4 SDS-PAGE gel showing purification steps of CjeNANAS (1 whole lysed cells, 2 supernatant, 
3 IMAC bound protein 4 insoluble protein, 4 IMAC bound protein, 5 IMAC flowthrough, 6 Desalt and 
TEV protease, 7 IMAC bound, 8 IMAC flow through, 9 SEC). 
 
2 3 4 5 6 7 8 9 1 ladder 
38 kDa 
38 kDa 
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As shown in lane seven of both gels (Figures 2.3 and 2.4), a large proportion of NANAS was 
lost in the flowthrough due to the incomplete TEV cleavage of His-tags. The cleavage of His-
tags may have not gone to completion due to the low temperature at which the TEV 
reactions were carried out or not left for sufficient time at this temperature.   
There are some impurities in lane nine of the gel shown in Figure 2.4 for the purification of 
CjeNANAS. The impurity corresponds to CjeNANAS with the His-tag still attached. Some of 
this protein which was not removed in the second IMAC, may have co-purified with the 
cleaved NANAS by intermolecular interactions or homodimer formation.  
According to the gel analysis, the impurity is relatively small when compared with the band 
corresponding to the protein of interest. The presence of the contaminant tagged protein 
does not change the catalytic reaction rate of the untagged NANAS, meaning that the effect 
of the impurity upon kinetic analysis of the purified enzyme is likely to be negligible.48  
2.3 PEP the natural substrate of NANAS 
PEP is a common anionic compound which has great significance in biochemical processes. 
This molecule is a small, three carbon compound which has three key functional groups 
(Figure 2.5); the carboxylic acid group, the phosphate group, and the double bond between 
C2 and C3.  
 
 
Figure 2.5 The three functional groups of PEP; A, phosphate group, B, carboxylic acid, and C, carbon-
carbon double bond. 
 
The key feature of PEP is that it is an enol, and thus nucleophilic at C3. However, the double 
bond is also conjugated to the carboxylic functionality, potentially making the compound 
electrophilic at C3 (Figure 2.6). 
 
A C 
B 
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Figure 2.6 The enol characteristic of PEP. 
 
PEP is synthesised during glycolysis in the reaction catalysed by enolase (Figure 2.7). 
Glycolysis is the catabolic pathway for the breakdown of glucose that ultimately forms 
pyruvate. This metabolic pathway is made up of 10 separate enzymatic reactions. One of 
these enzymatic reactions is the conversion of 2-phospho-D-glycerate into PEP by the action 
of enolase.  
 
 
Figure 2.7 Glycolysis and enzymatic reaction of enolase. 
 
PEP is a particularly important metabolite as it is an essential component in a wide variety of 
biological pathways, serving as a central precursor to many metabolic processes (Figure 2.8). 
Such metabolic processes include the Kreb’s cycle, the shikimate pathway, and 
gluconeogenesis.  PEP also serves as an alternative source of energy for bacteria, and it is 
utilised in the phosphotransferase system.  
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Figure 2.8 Examples of catalytic reactions and their enzymes, involving PEP. 
 
PEP is a highly efficient reactant and intermolecular bond formation is energetically 
favourable due to the high phosphate group transfer potential (ΔG = -14.8 kcal mol-1).49 The 
ΔG°´ of the hydrolysis of PEP is approximately -62 kJ mol-1, whereas that of a typical 
phosphate ester of an ordinary alcohol is approximately -13 kJ mol-1. This high phosphate 
transfer potential of PEP is due to the fact that the phosphate group traps the PEP structure 
in an energetically unstable enol form.49,50 Only after the phosphate transfer, the product 
pyruvate is formed which is relatively more stable than PEP, allowing PEP to have favourable 
transfer of the phosphate group. PEP undergoes a range of reactions by either cleaving the 
C-O bond to form a reactive pyruvyl group or the O-P bond to form a reactive phosphoryl 
group.49 
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There are four different modes of reaction by which PEP can act as a substrate (Figure 2.9):  
A. An addition reaction to the double bond. 
B. The addition of an electrophile from the C3 position of PEP leading to the cleavage of 
the P-O bond, transferring the phosphate group to the nucleophile. 
C. The addition of C3 position of PEP, as a nucleophile, to an electrophile. This is 
followed by the cleavage of the C-O bond and releasing the phosphate as an 
inorganic group.   
D. The addition followed by the elimination to generate a compound with an 
enolpyruvyl functional group, transferring phosphate to another molecule. This 
results in the cleavage of the C-O bond as well. 
 
 
 
Figure 2.9 Examples of the four different types of enzymatic reactions with PEP. 
 
The enzyme of interest in these studies, NANAS, catalyses the reaction with PEP in a form of 
“mode C” with C3 of PEP acting as a nucleophile on an aldehydic co-substrate and the 
reaction occuring via C-O cleavage of the C-O-P bond of PEP.2,9 The reaction results in a new 
C-C bond at the C3 position of PEP and the release of phosphate. The related enzymes, 
DAH7PS and KDO8PS also follow the same general mechanism of reaction with PEP, with 
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the exception of different stereochemistry. DAH7PS and KDO8PS catalyse the addition of 
PEP to the re rather than si face of their aldehydic substrates.44,47,51 
2.4 PEP analogues used in this study 
In previous studies, PEP analogues have been used to explore and understand the reaction 
mechanisms of PEP-utilising enzymes. 42,52-56 As NANAS is also a PEP-utilising enzyme, a 
range of PEP analogues were used to observe how the compounds interact with NANAS and 
disrupt catalysis. The analogues shown in Table 2.1 were tested as potential substrates or 
inhibitors against NANAS. The PEP analogues used in this study include sulfoenolpyruvate 
(SEP), allylic phosphonate, 3-methyl-PEP (Me-PEP), 3-fluoro-PEP (F-PEP), 3-chloro-PEP (Cl-
PEP), and 3-bromo-PEP (Br-PEP). The PEP-utilising enzymes investigated in the past using 
these analogues, include enzyme I of the phosphotransferase system (PTS), pyruvate kinase, 
PEP carboxylase and PEP enolase.37,52,57 
Table 2.1 Summary of PEP analogues tested on NmeNANAS and CjeNANAS. 
Analogues structure 
Sulfoenolpyruvate 
(SEP)  
Allylic phosphonate 
        
3-Methyl-PEP 
(Me-PEP)  
3-Fluoro-PEP 
(F-PEP)            
3-Chloro-PEP 
(Cl-PEP)  
3-Bromo-PEP 
(Br-PEP)  
 
The PEP analogues were tested on NmeNANAS and CjeNANAS to determine if the active site 
and the catalytic function of the enzyme could accommodate the modification of PEP 
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functionalities. SEP and the allylic phosphonate were tested to determine whether the 
enzyme could tolerate the substitution of the phosphate group of PEP. The 3–substituted 
PEP analogues were tested on the NANAS to determine whether the enzymes could tolerate 
PEP analogues with a range of different substituents at the C3 position. 
The PEP analogues used in this study were synthesised by Hemi Cumming and Scott 
Walker.42,51 
2.4.1 SEP 
SEP is a PEP analogue in which the phosphate group is replaced by a sulfate group, 
effectively replacing the phosphorus atom within PEP with a sulphur atom (Figure 2.10). 
 
  
Figure 2.10 PEP analogue, SEP 
 
The sulfate group of SEP is expected to mimic the phosphate group of PEP because past 
investigations have found evidence of sulfate ions occupying the phosphate binding sites of 
DAH7PS, as observed by X-ray crystallography.53,54,57 In previous studies, SEP was tested 
with pyruvate kinase. It was found that the sulfuryl group of SEP was transferred to ADP, 
further suggesting that the SEP may mimic the structural features of PEP.52 The sulfate 
group of SEP has structural similarities with the phosphate group from PEP as both groups 
have similar steric size, and the same molecular tetrahedral geometry. However, possible 
intolerance of the enzyme for the substitution of the phosphate group needs to be 
considered. One significant difference between the sulfate and the phosphate groups is the 
charge. SEP, which has a sulfate group substituted for the phosphate, has only one negative 
charge while the phosphate group is likely to have two negative charges at physiological pH 
(in addition to the negative charge on the carboxylic functionality). The use of SEP, bearing a 
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monoanionic functionality, may probe the importance of the dianionic phosphate group of 
PEP. 
2.4.2 Allylic phosphonate 
The allylic phosphonate is another PEP analogue which has an altered phosphate group. This 
analogue has a methyl phosphono group instead of a phosphate group, effectively replacing 
the bridging oxygen atom between C2 and the phosphorus atom with a methylene carbon 
(Figure 2.11). 
  
Figure 2.11 PEP analogue, allylic phosphonate 
 
A phosphate group is an excellent leaving group but a phosphonate group is a poor leaving 
group due to the strong C-P bond. This analogue was chosen for investigation, as the allylic 
phosphonate had previously been observed to cause moderate inhibition of DAH7PS.37  
However, the phosphonate functionality has significantly higher pKa values than the 
phosphate group which means that the phosphonate group of this analogue, is expected to 
be protonated at physiological pH. Therefore it is likely that allylic phosphonate is 
monoanionic, once again probing the importance of a dianionic phosphate group of PEP. 
2.4.3  3-Substituted PEP Analogues 
2.4.3.1   3-Halo-PEP 
Several C3-substituted PEP analogues were also investigated in this study. For the 3-halo-
PEP compounds one of the vinyl hydrogens is replaced by an electronegative halogen. Such 
analogues include F-PEP, Cl-PEP, and Br-PEP (Figure 2.12). 
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Figure 2.12 The 3-halo-PEP series (Z)-isomers 
 
These analogues were tested on a variety of PEP utilising enzymes exhibiting inhibition in 
past studies.52,56 In these studies the majority of PEP utilising enzymes were inhibited with 
the 3-substituted PEP analogues suggesting that the vinylic hydrogens bonded to the C3 
position of PEP are not important for the enzymes ability to utilise PEP, in catalysis.52 The 
inhibition did however vary from weak to strong depending on the enzyme. For example, 
(Z)-isomers of F-PEP and Cl-PEP weakly inhibited enzyme I of PTS, exhibiting an inhibition 
constant of 0.4 mM for both inhibitors. For pyruvate kinase the (Z)-isomers of F-PEP and Cl-
PEP both displayed significant inhibition, with inhibition constants of 57 nM and 39 nM for 
F-PEP and Cl-PEP respectively. (E)-Cl-PEP was also tested but this analogue was reported to 
inhibit pyruvate kinase 2400-fold less strongly than its (Z)-isomer. The results of this study 
highlight the observation that most PEP utilising enzymes appear to favour the (Z)-isomer of 
these 3-substituted analogues.52 
The highly electron withdrawing nature of the halogen substituents decreases the electron 
density in the double bond and therefore reduces the nucleophilicity of C3 of PEP, meaning 
that the 3-halo-PEP might be expected to be less reactive as substrates for NANAS. Whilst 
fluorine is more electronegative than both chlorine and bromine, fluorine is the smallest 
substituent. The 3-halo-PEP series therefore tests both electronic and steric effects at C3 
position.  
(Z) and (E)-isomers of these 3-substituted PEP analogues are possible. In this study, the 
analogues were predominantly (Z)-isomer with an approximate (Z):(E) ratio of 10:1, 4:1, and 
10:1 for F-PEP, Cl-PEP, and Br-PEP respectively. 
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Firstly, these analogues were tested to determine whether they were able to act as 
alternative substrates for the NANAS enzymes, and to determine whether the active sites 
and the catalytic functions of the enzymes can tolerate such substitutions at the C3 position 
of PEP. The analogues were further tested as inhibitors of NANAS. F-PEP is a known 
substrate for NmeNANAS as described in chapter one.29 This analogue was also tested in this 
study for comparison with the other analogues. 
2.4.3.2  3-Methyl-PEP (Me-PEP) 
Another C3-substituted PEP analogue used in this study was the 3-methyl-PEP (Me-PEP). 
This analogue has a methyl group at the C3 position of PEP (Figure 2.13). 
  
 
Figure 2.13 PEP analogue Me-PEP (Z)-isomer 
 
The methyl substituent has a similar size to the bromo substituent of the Br-PEP, but the 
electron donating nature of the methyl group is significantly different to the other 3-
substituted PEP analogues. This analogue is also in a mixture of a (Z) and (E)-stereo-isomers 
but this analogue is predominantly in the form of the (Z)-isomer, with an approximate (Z):(E) 
ratio of 4:1. 
Me-PEP was tested as an alternative substrate for NANAS to determine whether the active 
site and the catalytic function of the enzyme could accommodate the methyl substitution at 
the C3 position of PEP. It was also tested as an inhibitor of NANAS.  
The aforementioned PEP analogues were tested and their interactions with the enzyme 
were compared between two different types of NANAS; NmeNANAS and CjeNANAS. 
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2.5 Kinetic results 
Kinetic assays were performed on NmeNANAS and CjeNANAS as described in the materials 
and methods section. The initial reaction rate between PEP and ManNAc, catalysed by the 
enzyme, was measured via monitoring the loss of PEP over time. A series of measured initial 
rates of reaction were used to calculate kinetic constants including the Michaelis-Menten 
constant (KM) and inhibition constant (Ki), in order to characterise the effect of analogues on 
NANAS catalysis. 
2.5.1 Michaelis-Menten constant, KM, of PEP with NANAS 
Before investigating the effects of the PEP analogues on NmeNANAS and CjeNANAS, the 
kinetic constants for the natural substrate of the enzyme, PEP, were determined. 
The KM for PEP was obtained for both NmeNANAS and CjeNANAS. The kinetic data for the 
initial rate of reaction catalysed by NANAS at a constant concentration of ManNAc and 
increasing concentrations of PEP is represented as a Michaelis-Menten plot.  The Michaelis-
Menten plot was used to derive kinetic parameters using non-linear fitting (Figure 2.14). 
 
  
 
 
 
 
 
 Figure 2.14 Michaelis-Menten plots for PEP utilisation by (A) NmeNANAS and (B) CjeNANAS. Kinetic 
assays were performed using variable concentrations of PEP, a constant concentration of 11.3 mM 
ManNAc and were initiated with approximately 15 µg of the enzyme. The assay was completed at 
25 °C in Bis-tris-propane (BTP) buffer (50 mM) at pH 8. 
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The KM values of PEP for NmeNANAS and CjeNANAS were determined as 20 ± 1 µM and 70 ± 
10 µM respectively, whereas the kcat values were determined to be 1.13 s
-1 and 1.9 s-1 
respectively. This shows that both enzymes have a high affinity for PEP and require 
relatively small concentrations of the substrate PEP to achieve saturation (Table 2.2). 
Table 2.2 Table of Kinetic constants determined for NANAS with PEP. 
 
Enzyme PEP KM (µM) kcat (s
-1) kcat / KM PEP (s
-1/ µM) 
NmeNANAS 20 ± 1 1.13 ± 0.06 0.057 ± 0.006 
NmeNANAS past study 19 250 0.9 0.0036 
NmeNANAS past study 230 28 ± 3 3.1 ± 0.1 0.111 ± 0.003 
CjeNANAS 70 ± 10 1.9 ± 0.3 0.027 ± 0.008 
CjeNANAS past study 148 33 ± 1 1.7 ± 0.1 0.052 ± 0.005 
CjeNANAS past study 229 7300 1194 0.16 
 
The KM values obtained from the prepared enzymes were significantly smaller than the 
literature values for NmeNANAS and CjeNANAS which were 0.25 mM and 7.3 mM 
respectively.9,29 The literature kinetic constants obtained for NmeNANAS were determined 
by using a continuous coupled assay with NANA lyase, in a Tris acetic acid buffer (pH 8.3) at 
37 °C, while increasing the concentration of PEP and keeping the concentration of ManNAc 
constant.9 The literature value for the kinetic constant obtained for CjeNANAS were 
determined by the use of a stopped thiobarbiturate assay, measuring the rate of formation 
of NANA in a bicine buffer (pH 8) at 37 °C.29 Significant differences between the 
experimental values and the literature values are likely due to the different methods used, 
and the difference in the temperature at which the kinetic assays were performed. 
Literature values from past investigations using a similar method as this study obtained KM 
values for PEP for NmeNANAS and CjeNANAS of 28 µM and 33 µM respectively, which is in 
good agreement with the experimental values obtained in these studies.30 This literature KM 
(PEP) value for NmeNANAS was obtained by monitoring PEP consumption at 232 nm (ԑ = 2.8 
x 103 M-1cm-1) as a function of time. The assay was completed in BTP buffer (pH 7.5) at 25 °C, 
with variable concentrations of PEP and a fixed concentration of ManNAc.30,48 
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2.5.2 Testing PEP analogues for alternative substrate or inhibition 
Each of the PEP analogues were tested with NmeNANAS and CjeNANAS to determine if they 
act as alternative substrates for the enzyme, and to examine if they were capable to 
inhibiting the enzyme. If so, the inhibition constant, Ki, was obtained for each inhibitor. 
To test PEP analogues as potential alternative substrates for NANAS, enzyme activity was 
observed in the presence of the PEP analogue and ManNAc, but in the absence of PEP. High 
concentrations of enzymes were used to observe if any reaction was occurring between the 
PEP analogues and ManNAc. The exact wavelength at which each PEP analogue absorbs 
maximally is uncertain, however all PEP analogues share the same conjugated structure as 
PEP. Assuming PEP and the analogues absorb at similar wavelength, the wavelength of 232 
nm was used to measure the concentration-dependent absorbance of all PEP analogues. 
Any consumption of the alternative PEP analogue in the NANAS catalysed reaction would be 
expected to be observed by a decrease absorbance at 232 nm. The rate of reaction was 
measured in absorbance units per minute (Abs min-1).  
Due to the relatively high concentration of enzymes and substrates, cuvettes with a 0.2 cm 
pathlength were used to maintain an absorbance below 1 absorbance unit during all kinetic 
assays of enzymes with PEP analogues. If the absorbance is too high, the measurement of 
absorbance becomes less accurate as Beer’s law is no longer obeyed.  
2.5.2.1 Testing the PEP analogues with the modifications to the phosphate 
group 
SEP and allylic phosphonate were investigated to see if they function as alternative 
substrates for either NmeNANAS or CjeNANAS.  
SEP 
SEP was tested against NmeNANAS or CjeNANAS in the presence of ManNAc, and absence 
of PEP. High concentrations of enzymes (10-20 times those used in the standard assay with 
PEP) were used in these assays in order to detect relatively low reaction rates. The change in 
absorbance at 232 nm was monitored, however no decrease in the absorbance was 
observed for either enzyme, suggesting that SEP is not an alternative substrate for either 
NmeNANAS or CjeNANAS.  
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Allylic phosphonate  
The phosphonate was tested as an alternative substrate for NmeNANAS and CjeNANAS in a 
similar fashion. The change in absorbance at 232 nm was monitored, however no decrease 
in the absorbance was observed for either enzyme, suggesting that the allylic phosphonate 
is not an alternative substrate for either NmeNANAS or CjeNANAS. This result was expected 
as it was considered unlikely that this analogue would be able to undergo the catalytic cycle 
due to the presence of the non-cleavable C-P bond. 
2.5.2.2 Testing the 3-substituted PEP analogues 
The 3-substitituted PEP analogues Cl-PEP, Br-PEP, and Me-PEP were investigated as possible 
alternative substrates for NmeNANAS and CjeNANAS.  
F-PEP 
F-PEP, is one of the 3-substituted PEP analogues used to obtain an inhibition constant for 
this study. F-PEP is a known alternative substrate for NANAS and has been used previously 
to determine the stereospecificity of the NANAS catalysed reaction as mentioned in chapter 
1. A previous study which elucidated the stereospecificity of the NANAS catalysed reaction, 
reports that only the si face of PEP attacks the si face of the carbonyl group of ManNAc.29 
Using a reaction mixture containing F-PEP and ManNAc, NmeNANAS or CjeNANAS was used 
to initiate the reaction. Approximately 10 to 20 times more enzyme (approximately 100 – 
200 µg) was used to initiate the reaction than was used for the standard kinetic assays with 
PEP. A slow loss of absorbance with time was observed for NmeNANAS at a rate of 0.007 
Abs min-1. This is approximately four fold slower than the rate of reaction with the same 
concentration of natural substrates initiated with much lower concentration of NmeNANAS 
(approximately 10 µg).  Conversely, addition of CjeNANAS resulted in a relatively fast loss of 
absorbance over time with a rate of 0.020 Abs min-1 was observed. This rate is only one and 
a half fold slower than the reaction rate with the same concentration of natural substrates 
initiated with one tenth the amount of CjeNANAS. When the amount of enzyme used for 
initiation was doubled, the rate of reaction (for both NmeNANAS and CjeNANAS) increased 
proportionally, to 0.012 Abs min-1 and 0.038 Abs min-1 respectively, indicating that the 
observed absorbance losses was indeed due to the enzyme-catalysed reaction.   
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The observed absorbance loss at 232 nm using F-PEP with both NmeNANAS and CjeNANAS 
supports the previous finding that F-PEP is an alternative substrate for NANAS. The 
proportionate increase of reaction rate upon the increase of enzyme concentration provides 
strong evidence that F-PEP is an alternative substrate for NANAS and undergoes reaction 
with ManNAc.  
Cl-PEP 
NmeNANAS or CjeNANAS were used to initiate the reaction between Cl-PEP and ManNAc by 
adding approximately 10 to 20-fold more enzyme (approximately 100 – 200 µg) than used in 
the standard assays with PEP. Both NANASs were added to a cuvette containing a set 
concentration of Cl-PEP and ManNAc.  
A slow loss of absorbance at 232 nm was observed for both NmeNANAS and CjeNANAS with 
measured rates of 0.01 Abs min-1, and 0.0019 Abs min-1 respectively. The rate of reaction of 
NmeNANAS with Cl-PEP is three orders of magnitude slower than the reaction with the 
natural substrates at similar concentrations, and initiated with 10 µg of NmeNANAS. 
Conversely the rate of reaction for CjeNANAS with Cl-PEP is 16-fold slower than the reaction 
rate of with natural substrates at similar concentrations initiated with 10 µg of CjeNANAS.  
The kinetic assays were repeated using the same concentrations of Cl-PEP and ManNAc in 
the absence of PEP, but was initiated with twice the concentration of either the NmeNANAS 
or CjeNANAS enzymes. The rates of reaction did not increase proportionally to the increase 
of NmeNANAS with the rate only increasing to 0.013 Abs min-1 when 200 µg of enzymes was 
added. On the other hand, when the amount of CjeNANAS was doubled, the reaction rate 
also approximately doubled, to 0.0026 Abs min-1 which may suggest that Cl-PEP is a 
potential alternative substrate for CjeNANAS.  
Br-PEP 
Either NmeNANAS or CjeNANAS was used to initiate the reaction between Br-PEP and 
ManNAc, again at approximately 10 to 20 times higher enzyme concentration 
(approximately 100 – 200 µg) than used for the standard assay.  
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Loss of absorbance was observed as a function of time for both NmeNANAS and CjeNANAS, 
with rates of at 0.016 Abs min-1 and 0.00012 Abs min-1 respectively. The rate of reaction 
catalysed by NmeNANAS with Br-PEP is two-fold slower than the reaction rate of 
NmeNANAS with the same concentration of natural substrates, initiated with 10 µg enzyme. 
The rate of reaction catalysed by CjeNANAS is approximately 200 fold slower with Br-PEP, 
than the reaction rate of CjeNANAS with the same concentrations of its natural substrates 
and 10 µg enzyme. 
The kinetic assay was repeated using the same concentrations of Br-PEP and ManNAc but 
was initiated with twice the concentration of either NmeNANAS or CjeNANAS enzymes. The 
reaction rates did not increase proportionally with the increase of NmeNANAS. Conversely, 
when the concentration of CjeNANAS was doubled, the rate of reaction nearly doubled to 
0.0016 Abs min-1. This may suggest that Br-PEP is an alternative substrate for CjeNANAS but 
not NmeNANAS.  
Me-PEP 
Me-PEP was tested as an alternative substrate of NmeNANAS and CjeNANAS. 100 µg and 80 
µg of NmeNANAS and CjeNANAS respectively were used to initiate a reaction between set 
concentrations of Me-PEP and ManNAc.  
A change in the measured absorbance over time was observed indicating catalysis in the 
presence of the enzyme. A slow reaction rate was observed between Me-PEP and ManNAc 
with NmeNANAS and CjeNANAS as 0.0015 Abs min-1 and 0.0017 Abs min-1 respectively. The 
rate of reaction catalysed by NmeNANAS and CjeNANAS with Me-PEP is approximately 20-
fold slower than the rate of reaction of NmeNANAS and CjeNANAS with similar 
concentration of their natural substrates, and initiated with 10 µg of enzyme.  
The kinetic assay was repeated using the same concentrations of Me-PEP and ManNAc but 
was initiated with twice the concentration of either NmeNANAS or CjeNANAS. The rates of 
reaction did not did not increase proportionally to the increase of both NmeNANAS and 
CjeNANAS indicating that Me-PEP is not a viable alternate substrate for either enzyme.  
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2.5.3 Inhibition of NANAS with PEP analogues 
The inhibition constants for each inhibitor tested against both orthologues of NANAS were 
determined. Generally, significantly lower Ki values were obtained with CjeNANAS in 
comparison to NmeNANAS. Each Ki was determined from nonlinear fitting the inhibition 
data, and the data is also displayed as a Lineweaver-Burke plot. 
Although some of the tested PEP analogues were determined to be alternative substrates 
for NANAS (section 2.5.2), their rates of reaction were very slow in comparison to the 
reaction with natural substrate PEP, and their reactions were only observable in the 
presence of very high concentrations of enzyme. Therefore, any effect the alternative 
substrates (reacting with ManNAc) may have upon the determination of Ki for each PEP 
analogue should be negligible. 
2.5.3.1 Inhibition by PEP analogues with the modifications to the phosphate 
group 
2.5.3.1.1 Inhibition of NmeNANAS or CjeNANAS with SEP  
SEP was assumed to be a possible inhibitor due to its structural similarities with PEP, 
however no significant inhibition was detected for both homologues of NANAS in the 
presence of 1 mM or 4 mM SEP. 
2.5.3.1.2 Inhibition of NmeNANAS or CjeNANAS with the allylic phosphonate 
Allylic phosphonate was tested for inhibition of NmeNANAS and CjeNANAS. No inhibition 
was observed upon addition of 0.8 mM and 1.0 mM allylic phosphonate respectively.  
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2.5.3.2 Inhibition of NANAS with the 3-substituted PEP analogues 
2.5.3.2.1 Inhibition of NmeNANAS with Me-PEP 
The inhibition assay of NmeNANAS with Me-PEP was used to obtain a Ki of 0.8 mM ± 0.1 
mM, this being the poorest inhibition of NmeNANAS observed for any of the PEP analogues 
(Figure 2.15). The obtained Ki of Me-PEP is approximately 40 times greater than the 
measured KM of PEP. Me-PEP showed competitive inhibition with respect to PEP. 
 
 
 
 
 
Figure 2.15 (A) Raw data and (B) Lineweaver-Burke plot of NmeNANAS inhibition with Me-PEP. 
Kinetic assays were performed using varied concentrations of PEP, 10.9 mM ManNAc and were 
initiated with approximately 10 µg of the enzyme. The kinetic assay was repeated with the additional 
presence of 0.68 mM and 1.35 mM Me-PEP.  The assay was completed at 25 °C in BTP buffer (50 
mM) at pH 8. 
 
2.5.3.2.2 Inhibition of CjeNANAS with Me-PEP 
The inhibition assay of CjeNANAS with Me-PEP was used to obtain a Ki of 23 ± 2 µM for Me-
PEP, exhibiting competitive inhibition with respect to PEP (Figure 2.16). This value is 
approximately three times lower than the measured KM of PEP for CjeNANAS. This indicates 
that the inhibition of CjeNANAS with Me-PEP is surprisingly potent. As described below, this 
compound is still one of the poorest inhibitors of CjeNANAS; however, the Ki of Me-PEP for 
CjeNANAS is significantly lower than that of NmeNANAS with Me-PEP, demonstrating that 
Me-PEP is a far more efficient inhibitor of CjeNANAS than NmeNANAS. 
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Figure 2.16 (A) Raw data and (B) Lineweaver-Burke plot of CjeNANAS Inhibition with Me-PEP. Kinetic 
assays were performed using varied concentrations of PEP, a constant concentration of 10.1 mM 
ManNAc and were initiated with approximately 15 µg of enzyme. The kinetic assay was repeated 
with the additional presence of 0.041 mM and 0.081 mM Me-PEP.  The assay was completed at 
25 °C in BTP buffer (50 mM) at pH 8. 
 
2.5.3.2.3 Inhibition of NmeNANAS with F-PEP  
The inhibition assay of NmeNANAS with F-PEP was used to obtain a Ki of 0.19 ± 0.02 mM, 
exhibiting competitive inhibition with respect to PEP (Figure 2.17). This value is 
approximately 9.5 times greater than the measured KM of PEP for NmeNANAS. F-PEP is a 
stronger inhibitor than Me-PEP for NmeNANAS.  
 
 
 
 
 
Figure 2.17 (A) Raw data and (B) Lineweaver-Burke plot of NmeNANAS Inhibition with F-PEP. Kinetic 
assays were performed using varied concentrations of PEP, a constant concentration of 10.8 mM 
ManNAc and were initiated with approximately 10 µg of enzyme. The kinetic assay was repeated 
with the additional presence of 0.41 mM and 0.82 mM F-PEP.  The assay was completed at 25 °C in 
BTP buffer (50 mM) at pH 8. 
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2.5.3.2.4 Inhibition of CjeNANAS with F-PEP  
The inhibition assay of CjeNANAS with F-PEP was used to obtain a Ki of 24 ± 2 µM, exhibiting 
competitive inhibition with respect to PEP (Figure 2.18). This value is about three-fold lower 
than the measured KM of PEP for CjeNANAS. This suggests that F-PEP is a strong inhibitor for 
CjeNANAS. The relative potency of F-PEP as an inhibitor compared to the KM of PEP for 
CjeNANAS, seems to be similar to that of Me-PEP with CjeNANAS. 
 
 
 
 
 
Figure 2.18 (A) Raw data and (B) Lineweaver-Burke plot of CjeNANAS Inhibition with F-PEP. Kinetic 
assays were performed using varied concentrations of PEP, a constant concentration of 10.05 mM 
ManNAc and were initiated with approximately 15 µg of the enzyme. The kinetic assay was repeated 
with the additional presence of 0.032 mM and 0.065 mM F-PEP.  The assay was completed at 25 °C 
in BTP buffer (50 mM) at pH 8. 
 
2.5.3.2.5 Inhibition of NmeNANAS with Cl-PEP  
The inhibition assay of NmeNANAS with Cl-PEP was used to obtain a Ki of 0.10 ± 0.01 mM, 
this value is about five times greater than the measured KM of PEP for NmeNANAS (Figure 
2.19). Cl-PEP exhibits competitive inhibition with respect to PEP. Cl-PEP is a more potent 
inhibitor than F-PEP for NmeNANAS. 
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Figure 2.19 (A) Raw data and (B) Lineweaver-Burke plot of NmeNANAS Inhibition with Cl-PEP. Kinetic 
assays were performed using varied concentrations of PEP, a constant concentration of 10.9 mM 
ManNAc and were initiated with approximately 10 µg of the enzyme. The kinetic assay was repeated 
with the additional presence of 0.21 mM and 0.42 mM Cl-PEP.  The assay was completed at 25 °C in 
BTP buffer (50 mM) at pH 8. 
 
2.5.3.2.6 Inhibition of CjeNANAS with Cl-PEP  
The inhibition assay of CjeNANAS with Cl-PEP was used to obtain a Ki of 3.3 ± 0.4 µM, 
exhibiting competitive inhibition (Figure 2.20). This value is about 20-fold smaller than the 
measured KM of PEP for CjeNANAS. This is a very strong inhibitor and it is the PEP analogue 
which displays the most potent inhibition of CjeNANAS.  
 
 
 
 
 
Figure 2.20 (A) Raw data and (B) Lineweaver-Burke plot of CjeNANAS Inhibition with Cl-PEP. Kinetic 
assays were performed using varied concentrations of PEP, a constant concentration of 11.15 mM 
ManNAc and were initiated with approximately 10 µg of the enzyme. The kinetic assay was repeated 
with the additional presence of 0.012 mM and 0.025 mM Cl-PEP.  The assay was completed at 25 °C 
in BTP buffer (50 mM) at pH 8. 
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2.5.3.2.7 Inhibition of NmeNANAS with Br-PEP  
The inhibition assay of NmeNANAS with Br-PEP was used to obtain a Ki of 0.096 ± 0.007 mM, 
exhibiting competitive inhibition with respect to PEP (Figure 2.21). This value is about 4.8 
times greater than the measured KM of PEP for NmeNANAS. Br-PEP is a strong inhibitor 
which has the lowest Ki of the PEP analogues tested against NmeNANAS. The potency of F-
PEP as an inhibitor seems to be similar to that of Me-PEP with CjeNANAS.  
 
 
 
 
 
Figure 2.21 (A) Raw data and (B) Lineweaver-Burke plot of NmeNANAS Inhibition with Br-PEP. Kinetic 
assays were performed using varied concentrations of PEP, a constant concentration of 20.2 mM 
ManNAc and were initiated with approximately 10 µg of the enzyme. The kinetic assay was repeated 
with the additional presence of 0.40 mM and 0.75 mM Br-PEP.  The assay was completed at 25 °C in 
BTP buffer (50 mM) at pH 8. 
 
2.5.3.2.8 Inhibition of CjeNANAS with Br-PEP 
The inhibition assay of CjeNANAS with Br-PEP was used to obtain a Ki of 3.6 ± 0.4 µM, 
exhibiting competitive inhibition with respect to PEP (Figure 2.22). This value is 
approximately 19 times lower than the measured KM of PEP for CjeNANAS. Br-PEP is a strong 
inhibitor of CjeNANAS but the obtained Ki is only slightly higher than that of Cl-PEP 
compared to the KM of PEP for CjeNANAS.  
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Figure 2.22 (A) Raw data and (B) Lineweaver-Burke plot of CjeNANAS Inhibition with Br-PEP. Kinetic 
assays were performed using varied concentrations of PEP, a constant concentration of 11.2 mM 
ManNAc and were initiated with approximately 10 µg of the enzyme. The kinetic assay was repeated 
with the additional presence of 0.013 mM and 0.025 mM Br-PEP.  The assay was completed at 25 °C 
in BTP buffer (50 mM) at pH 8. 
 
2.5.4 Summary of the kinetic analysis with PEP analogues 
The kinetic constants that were determined for NmeNANAS and CjeNANAS with each of the 
PEP analogues are summarised in Table 2.3.  
The only PEP analogue which exhibited activity as an alternative substrate for NmeNANAS 
was F-PEP, whereas F-PEP, Cl-PEP and Br-PEP all demonstrated loss of absorbance at 232 nm 
for CjeNANAS, in line with their possible utilisation as alternative substrates of this enzyme. 
In all cases the reactions were very slow and observable only if more than ten times the 
amount of enzyme (approximately 100 µg – 200 µg) was used to initiate the reaction than 
was normally employed for assays with PEP. Therefore without full characterisation of the 
substituted NANA products, their role as substrates cannot be confirmed. It is noted that F-
PEP has already been characterised as a substrate for NmeNANAS.29 In future studies, the 
full kinetic constants may be investigated for F-PEP against NmeNANAS using the continuous 
assay system used in these studies. In addition, it should be possible to confirm that F-PEP is 
a substrate of CjeNANAS via product identification between F-PEP and NANAS reaction. 
Ki values were determined for the PEP analogues against both NANAS enzymes, except for 
SEP and the allylic phosphonate analogue which did not exhibit inhibition. All inhibitors of 
NANAS were found to exhibit competitive inhibition with respect to PEP. The obtained Ki 
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values for NmeNANAS were typically larger than those obtained for CjeNANAS in 
comparison to their respective KM (PEP) values. 
For the PEP analogues tested against NmeNANAS, Me-PEP exhibited the poorest inhibition. 
The strongest inhibition of NmeNANAS was obtained by Br-PEP followed by Cl-PEP and F-
PEP.  
For CjeNANAS, the poorest inhibitors were Me-PEP and F-PEP. The strongest inhibition was 
observed by Cl-PEP and Br-PEP. Given the relatively large size of both the bromo and chloro 
substituents this result was unexpected. 
Table 2.3 Summary of NANAS inhibition with PEP analogues 
 
Name Structure NmeNANAS Ki CjeNANAS Ki 
Alternative 
substrate for 
NmeNANAS 
Alternative 
substrate for 
CjeNANAS 
SEP 
 
NA NA No No 
Allylic phosphonate 
 
NA NA No No 
Me-PEP 
 
0.8 ± 0.1 mM 23 ± 2 µM No No 
F-PEP 
 
0.19 ± 0.02 mM 24 ± 2 µM Yes Yes 
Cl-PEP 
 
0.10 ± 0.01 mM 3.3 ± 0.4 µM No Yes 
Br-PEP 
 
0.096 ± 0.007 mM 3.6 ± 0.4 µM No Yes 
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Chapter 3           
Kinetic assays with ManNAc analogues and a 
NANA analogue 
3.1 Introduction 
The previous chapter was concerned with the range of substrate analogues that are similar 
in structure to PEP, the natural substrate for NmeNANAS and CjeNANAS. The other natural 
substrate utilised by NmeNANAS and CjeNANAS is ManNAc, which reacts with PEP to 
produce NANA.    
Since the goal of this research was to test various substrate and product analogues on wild-
type NmeNANAS and CjeNANAS, this chapter describes a series of experiments in which a 
range of ManNAc analogues and a NANA analogue were tested as alternative substrates and 
inhibitors of NANAS.  
3.2 ManNAc the natural substrate 
ManNAc is the natural substrate for the enzymatic synthesis of NANA by NANAS. This 
compound is a monosaccharide, comprising a six carbon chain and an aldehyde functional 
group. Hydroxyl groups are found at positions C3, C4, C5 and C6 and an N-acetyl group is 
located at the C2 position (Figure 3.1). 
 
Figure 3.1 The key functional groups of ManNAc; (A) aldehyde group, and (B) N-acetyl group. 
ManNAc is capable of cyclisation, forming either a pyranose or a furanose ring. 
 
A 
B 
ManNAc Pyranose  ManNAc Furanose  
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Whilst ManNAc can exist as a linear compound, the presence of the aldehyde group allows 
ManNAc to undergo cyclisation to both hemiacetal pyranose and furanose forms (Figure 
3.1). The position of the equilibrium favours the formation of the α-anomer of the pyranose 
form over the β-anomer of pyranose and both furanose forms.58 The percentage of the 
equilibrium position of the structurally related molecule mannose is 67%, 33%, 0%, and 0% 
for α-pyranose, β-pyranose, α-furanose, and β-furanose respectively.58 It is assumed that 
the cyclic structure of ManNAc is more prevalent due to the thermodynamic favourability 
and stability of the six-membered pyranose, however it is the open form of ManNAc that 
binds to the active site of NANAS and undergoes reaction with PEP. Although the 
mutarotation of ManNAc is a “facile” process, the sugar substrate predominantly exists in a 
closed ring form. The reaction must proceed using the open ring form of ManNAc thus it is 
likely that the NANAS catalyses the ring opening of ManNAc prior to reaction.59 
According to the proposed reaction mechanism of NANAS the open chain form of ManNAc 
binds to the active site, so that the aldehyde functionality at position C1 is exposed for 
catalysis.3,9 Crystallographic analysis of NmeNANAS in complex with PEP, Mn2+, and 
rManNAc supports the proposed reaction mechanism, which shows the metal ion 
coordinating the hydroxyl group at the C1 position of rManNAc. For ManNAc the metal ion 
would activate the aldehyde functionality to nucleophilic attack on its carbonyl carbon.3,9 
As explained in Chapter 1, the N-acetyl group of ManNAc is a key functionality which is used 
by the enzyme to orientate ManNAc in the active site. The aldehyde group gives ManNAc its 
reactive functionality with PEP. In these studies, ManNAc analogues with modifications of 
the N-acetyl group and the aldehyde group were investigated to determine the effects of 
such modifications on the catalytic properties of NANAS. 
ManNAc is synthesised in biological systems by the enzyme UDP-N-acetylglucosamine 
epimerase. This enzyme converts UDP-N-acetylglucosamine (UDP-GlcNAc) into ManNAc 
(Figure 3.2).2 
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Figure 3.2 Biosynthesis of ManNAc. 
 
Not only is ManNAc a precursor for sialic acid biosynthesis but may also play other 
important physiological roles. For example, ManNAc has been shown that ManNAc 
improves object recognition and hippocampal cell proliferation in mice, suggesting that 
ManNAc may be related to cognitive development and age-related dementia in mammals.60 
Currently there are clinical studies and trials investigating the therapeutic potential of 
ManNAc for the treatment of patients with severe neurodegenerative disorders caused by 
the defective gene which encodes UDP-GlcNAc.21,61  
In bacteria, ManNAc is incorporated into common antigens and is also an alternative source 
of energy via catabolism, since ManNAc is a good source of carbon and nitrogen.23,62  
3.3 ManNAc analogues used in this study 
A variety of ManNAc analogues were tested against both NmeNANAS and CjeNANAS (table 
3.1). The analogues were chosen based on their structural similarity to the natural substrate 
ManNAc, with the idea that the analogues might be able to access the ManNAc binding site 
of the enzyme. The ManNAc analogues displayed in Table 3.1 were tested as potential 
substrates or inhibitors against both NANAS enzyme. The ManNAc analogues used for this 
study include N-acetylmannosaminitol (rManNAc), N-acetyl-D-glucosamine (GluNAc), N-
acetyl-D-galactosamine (GalNAc), D-Mannosamine Hydrochloride (ManCl), and 2-deoxy-D-
glucose (2DG).  
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Table 3.1 Summary of ManNAc analogues tested against NmeNANAS and CjeNANAS. The displayed 
ManNAc analogues which are capable of cyclisation are depicted as pyranose forms because they 
are the most thermodynamically stable. 
 
Analogues structure 
N-Acetylmannosaminitol 
(rManNAc) 
 
N-Acetyl-D-glucosamine 
(GluNAc)  
N-Acetyl-D-galactosamine 
 (GalNAc) 
 
D-Mannosamine Hydrochloride 
(ManCl)            
2-Deoxy-D-glucose 
(2DG)  
 
The ManNAc analogues were tested as potential substrates for NmeNANAS and CjeNANAS 
to determine if the active site and the catalytic function of the enzymes could accommodate 
the substitution or alteration of the stereochemistry of the ManNAc functionalities. 
rManNAc was used to determine whether the enzyme active site could accomodate the 
reduced aldehyde group. GluNAc and GalNAc were tested with NANAS to determine 
whether the enzymes could utilise analogues with alternative stereochemistry. ManCl was 
tested to determine whether NANAS could tolerate the substitution of the N-acetyl group 
whilst 2DG was tested to determine whether NANAS could utilise a sugar substrate lacking 
the N-acetyl group entirely.  
In a past study, GluNAc and GalNAc were tested on NANAS from Streptococcus agalactaie 
(SagNANAS) as part of an investigation into the substrate specificity of SagNANAS.63 GluNAc 
and GalNAc responded positively with SagNANAS suggesting the importance of the N-acetyl 
group at the C2 position for catalytic activity.63 
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3.3.1 Aldehyde altered ManNAc analogue 
3.3.1.1 rManNAc 
This ManNAc derived analogue has the functional group reduced to a primary alcohol 
(Figure 3.3). The reduction of the carbonyl group also prevents this analogue from forming a 
cyclic structure. Since this analogue no longer carries the reactive carbonyl of the aldehyde 
functional group, this compound is no longer susceptible to a nucleophilic attack by PEP, 
therefore preventing the reaction within the enzyme. rManNAc was tested on NmeNANAS 
and CjeNANAS because it had been previously used as a substitute for ManNAc in the X-ray 
crystal structure of ligand bound NmeNANAS (PDB code 1XUZ).3,9 rManNAc was tested to 
determine whether the removal of an aldehyde group would affect the kinetic properties 
with NANAS and to determine the level of inhibition afforded by this compound.  
 
  
Figure 3.3 ManNAc and analogue N-acetylmanosaminitol 
 
3.3.2 N-Acetyl altered ManNAc analogue 
Previous studies have shown that cells readily take up and metabolise N-acetyl modified 
ManNAc analogues to synthesise their respective modified sialic acids, suggesting that 
NANAS may be able to accommodate ManNAc analogues with their N-acetyl functional 
group altered.64,65 ManNAc analogues mentioned earlier in this chapter (GluNAc, GalNAc, 
ManCl, and 2DG), which have modified N-acetyl groups, were tested as alternative sugar 
substrates for NmeNANAS and CjeNANAS. 
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3.3.2.1 GluNAc and GalNAc 
GluNAc and GalNAc are ManNAc analogues which were used to investigate the importance 
of the conformational position of the N-acetyl group for catalysis by NANAS (Figure 3.4). 
    
Figure 3.4 Pyranose forms of ManNAc and analogues N-acetylglucosamine (GluNAc) and N-
acetylgalactosamine (GalNAc). 
 
The configuration of the N-acetyl functional group at C2 for GluNAc is different to that of 
ManNAc. The C2 N-acetyl group of ManNAc is in (R)-configuration whereas GluNAc has an 
(S)-configuration. GluNAc in the lowest energy conformer of its pyranose form, has an N-
acetyl functional group on an equatorial position. GalNAc on the other hand, is an isomer of 
GluNAc with the hydroxyl group at the C4 position in an axial position, and an (S)-
configuration in the lowest energy conformer. 
Due to their structural similarity with ManNAc, GluNAc and GalNAc may competitively 
inhibit NANAS. However, the analogues may bind poorly with the ManNAc binding site given 
that the configuration of the N-acetyl functional group, which is a key component for 
substrate recognition, has been altered. 
3.3.2.2 ManCl 
ManCl is an analogue of the natural sugar substrate, ManNAc (Figure 3.5). This ManNAc 
analogue lacks the acetyl group present on the C2 amino group of ManNAc. ManCl was 
tested to probe the importance of the N-acetyl functionality of ManNAc for substrate 
recognition and catalysis of NANAS. 
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Figure 3.5 ManNAc and analogue ManCl 
 
3.3.2.3 2DG 
2DG is a ManNAc analogue which was used to investigate how the lack of an N-acetyl 
functional group might affect NANAS activity (Figure 3.6). The difference between this 
analogue and the natural substrate is that the N-acetyl group and the amine functionality at 
the C2 position have been completely removed. 
 
Figure 3.6 ManNAc and analogue 2DG 
 
As mentioned in the first chapter, the N-acetyl group of ManNAc is not required for the 
binding of the substrate into the active site but for driving ManNAc into a favourable 
orientation within the active site for catalysis.30 2DG mimics the structure of ManNAc, but 
the lack of an N-acetyl group may alter 2DG’s ability to act as an alternative substrate. 
3.4 Kinetic assay results 
Kinetic assays were performed on NmeNANAS and CjeNANAS as described in the materials 
and method section. The initial reaction rate between PEP and ManNAc, catalysed by the 
enzyme, was measured as the loss of PEP over time. A series of measured initial rates of 
reaction were used to calculated kinetic constants including the Michaelis-Menten constant 
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(KM) and inhibition constant (Ki) in order to characterise the effect of ManNAc analogues on 
the two wild-type NANAS enzymes. 
3.4.1 Michaelis-Menten constant (KM) of ManNAc with NANAS 
Resulting to the studies described in the previous chapter, before investigating any kinetic 
effects from the use of ManNAc analogues on NmeNANAS and CjeNANAS, the kinetic 
constants for the natural substrate, ManNAc, were determined. 
The apparent KM values for ManNAc were obtained for both NmeNANAS and CjeNANAS. The 
kinetic data for the initial rate of reaction catalysed by NANAS at a constant concentration 
of PEP and increasing concentrations of ManNAc are represented as a Michaelis-Menten 
plot which was used to derive kinetic parameters using non-linear fitting (Figure 3.7). 
 
      
Figure 3.7 Michaelis-Menten plots for ManNAc utilisation by (A) NmeNANAS and (B) CjeNANAS. 
Kinetic assays were performed using increasing concentrations of ManNAc, constant concentration 
of 0.32 mM PEP, and were initiated with approximately 15 µg of the enzyme. The assay was 
completed at 25 °C in BTP buffer (50 mM) at pH 8. 
 
The KM values of ManNAc for NmeNANAS and CjeNANAS were determined as 1300 ± 100 
µM and 860 ± 90 µM respectively, while the kcat values were determined to be 1.13 s
-1 and 
1.9 s-1 respectively. The KM values obtained for both orthologues of NANAS indicate that 
both enzymes have a relatively low affinity for ManNAc and require high substrate 
concentrations to achieve saturation (Table 3.2). 
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Table 3.2 Table of Kinetic constants for NANAS with ManNAc 
Enzyme ManNAc KM (µM) kcat (s
-1) kcat / KM ManNAc (s
-1 µM-1) 
NmeNANAS 1300 ± 100 1.13 ± 0.06 0.057 ± 0.06 
NmeNANAS past study 130 2900 ± 200 3.1 ± 0.1 11 x 10-4 ± 1 x 10-4 
NmeNANAS past study 29 9400 0.9 9.57 x 10-5 
CjeNANAS 860 ± 90 1.9 ± 0.3 0.027 ± 0.008 
CjeNANAS past study 148 4900 ± 200 1.7 ± 0.1 3.5 x 10-4 ± 3 x 10-5 
CjeNANAS past study 229 17600 1194 0.068 
 
The KM values obtained for the prepared enzymes were significantly smaller than the 
literature values reported for NmeNANAS (9.4 mM)9 and CjeNANAS (17.6 mM)29. The kinetic 
constants reported in the literature obtained for NmeNANAS were determined by using a 
continuous coupled assay with NANA lyase, in a Tris acetate buffer (pH 8.3) at 37 °C. The 
literature values for the kinetic constants obtained for CjeNANAS were determined by the 
use of a thiobarbiturate assay, measuring the rate of formation of NANA in bicine buffer (pH 
8) at 37 °C.29 Significant differences between the experimental values and the literature 
values are likely due to the variation in methodologies of the kinetic assays used and the 
different temperatures at which the kinetic assays were performed. Literature values from 
previous investigations using a similar kinetic method as this study obtained a KM value for 
ManNAc of 2.9 mM and 4.9 mM for NmeNANAS and CjeNANAS respectively, which is closer 
in magnitude to the experimental value than the aforementioned reported value but still 
approximately three fold larger for NmeNANAS and six fold larger for CjeNANAS.30,48 This 
difference may be due to the difference in assay pH or other experimental variations.  
3.4.2 Testing ManNAc analogues as alternative substrates or inhibitors 
Kinetic assays were performed using NmeNANAS and CjeNANAS with ManNAc analogues as 
described in the previous section. The ManNAc analogues were tested on the enzymes to 
determine whether the analogues could act as viable alternative substrates of the enzyme 
and/or if they were able to inhibit enzyme activity. If so, the inhibition constants were 
obtained for each compound using kinetic analysis. 
To verify whether or not a ManNAc analogue was an alternative substrate, the activity of 
the enzyme was determined in the presence of the ManNAc analogue and PEP but in the 
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absence of ManNAc. As with the kinetic procedures described in Chapter two, high 
concentrations of enzymes were required (more than ten times the amount of enzyme used 
in standard assays with natural substrate ManNAc), to observe the rate of catalytic reaction 
between the ManNAc analogues and PEP. 
Any utilisation of ManNAc analogues in the enzyme catalysed reaction would result in a 
decrease of PEP concentration in the reaction mixture, which would be observed by a 
concentration-dependent loss of absorbance at 232 nm. The rate of reaction was measured 
as absorbance per minute (Abs min-1). 
3.4.2.1 The analogue rManNAc is not an alternative substrate 
The reduced form of ManNAc (rMAnNAc) is not an alternative substrate for either 
NmeNANAS or CjeNANAS. This is likely due to the absence of the reactive carbonyl 
functionality of the aldehyde group in rManNAc. Nucleophilic attack by PEP cannot occur 
with rManNAc, preventing catalysis. Therefore rManNAc was not investigated to determine 
whether the analogue could act as an alternative substrate.  
3.4.2.2 Analysis of other ManNAc analogues 
Several ManNAc analogues were investigated as potential alternative substrates for 
NmeNANAS and CjeNANAS. 
Each ManNAc analogue, was tested as an alternative substrate by initiating the enzymatic 
reaction with high concentration of either NmeNANAS or CjeNANAS (approximately 50 µg). 
Enzyme was added to a reaction mixture containing PEP and the ManNAc analogue at fixed 
concentrations, in the absence of ManNAc. None of the tested analogues showed activity 
with either enzyme with the exception of 2DG which had slow reaction rate of only 0.0041 
Abs min-1. When the enzyme concentration was doubled for the same conditions, a rate of 
0.0057 Abs min-1 was observed. The proportional increase of reaction rate with respect to 
the increase of enzyme concentration suggests that 2DG may be an alternative substrate for 
NANAS. To conclusively prove that this was a substrate for the enzyme, the alternative 
NANA product would need to be isolated and characterised completely. Due to the 
extremely low reaction rates observed in this study this further analysis was not performed. 
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3.4.3 Inhibition of NANAS with ManNAc analogues 
3.4.3.1 Inhibition of NmeNANAS with rManNAc 
The inhibition of NmeNANAS with rManNAc gave a Ki value of 320 ± 30 µM, and therefore 
appears to be a relatively weak inhibitor of NmeNANAS (Figure 3.8). The obtained Ki value 
for rManNAc is approximately four times smaller than the measured KM of ManNAc which 
indicates that rManNAc is a relatively strong inhibitor of NmeNANAS, with respect to the 
natural substrate.   
 
 
 
 
 
 
Figure 3.8 (A) Raw data and (B) Lineweaver-Burke plots of NmeNANAS Inhibition with rManNAc. 
Kinetic assays were performed using variable concentrations of ManNAc, a constant concentration 
of 0.22 mM PEP and were initiated with approximately 15 µg of the enzyme. The kinetic assay was 
repeated with the additional presence of 1.05 mM and 2.2 mM rManNAc.  The assay was completed 
at 25 °C in BTP buffer (50 mM) at pH 8. 
 
3.4.3.2 Inhibition of CjeNANAS with rManNAc 
The inhibition analysis of CjeNANAS with rManNAc produced at Ki value of 9 ± 2 µM and 
appears to exhibit uncompetitive inhibition (Figure 3.9). The obtained Ki value of rManNAc 
is approximately 96 times lower than the measured KM of ManNAc for CjeNANAS which 
indicates that rManNAc is a relatively strong inhibitor of CjeNANAS. The uncertainty for this 
Ki value is approximately 22% which is a large margin of error to be concerned. The plots on 
the double reciprocal graph indicate that the mode of inhibition for CjeNANAS with 
rManNAc is likely to be uncompetitive rather than competitive inhibition.   
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Figure 3.9 (A) Raw data and (B) Lineweaver-Burke plots of CjeNANAS Inhibition with rManNAc. 
Kinetic assays were performed using varied concentrations of ManNAc, a constant concentration of 
0.29 mM PEP and were initiated with approximately 15 µg of the enzyme. The kinetic assay was 
repeated with the additional presence of 0.013 mM and 0.025 mM rManNAc.  The assay was 
completed at 25 °C in BTP buffer (50 mM) at pH 8. 
 
3.4.3.3 Kinetic assays of NANAS with other ManNAc analogues 
NmeNANAS and CjeNANAS were tested with the ManNAc analogues, GluNAc, GalNAc, 
ManCl, and 2DG to probe whether these analogues exhibit inhibition. It was expected that 
GluNAc and GalNAc would show some inhibition of the enzyme because both analogues 
contain the important N-acetyl functionality. The N-acetyl group is recognised by the key 
conserved amino acid residue, Arg-314.30 The remaining two analogues, ManCl and 2DG 
were expected to show weak or no inhibition of the enzyme because their N-acetyl group is 
altered (in ManCl) or abscent (in 2DG).  
The kinetic assay was initiated with approximately 10 µg of either NmeNANAS or CjeNANAS 
at 25 °C. Fixed concentration of PEP and ManNAc were used to determine the control rate 
of loss of PEP over time at 232 nm. The assay was repeated in the presence of various 
ManNAc analogues and the rates of loss of absorbance over time were compared to the 
control rate (Figure 3.10 and Figure 3.11).  
All ManNAc analogues were present in greater concentration (10 mM) than the 
concentration of ManNAc (0.16 mM and 0.49 mM for testing against NmeNANAS and 
CjeNANAS respectively) in the reaction mixture, to ensure that any inhibition by these 
analogues could be observed. 
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Figure 3.10 Relative activity measurements of CjeNANAS with ManNAc analogues. Kinetic assays 
were performed at a constant concentration of ManNAc (0.16 mM) and a constant concentration of 
PEP (1.91 mM) and were initiated with approximately 10 µg of the enzyme to determine the control 
rate of loss PEP (control). The kinetic assay was then repeated in the above conditions with the 
additional presence of ManNAc analogues (10 mM).  The assay was completed at 25 °C in BTP buffer 
(50 mM) at pH 8. 
 
 
 
 
 
 
 
Figure 3.11 Relative activity measurements of CjeNANAS with ManNAc analogues. Kinetic assays 
were performed at a constant concentration of ManNAc (0.49 mM) and a constant concentration of 
PEP (0.29 mM) and were initiated with approximately 15 µg of the enzyme to determine the control 
rate of loss PEP (control). The kinetic assay was then repeated in above conditions with each 
additional presence ManNAc analogues (10 mM).  The assay was completed at 25 °C in BTP buffer 
(50 mM) at pH 8. 
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The ManNAc analogues tested showd little evidence of inhibition. GluNAc and GalNAc, 
which were expected to show some degree of inhibition, were unable to significantly retard 
the rate of consumption of PEP. As stated, all ManNAc analogue concentrations were 
present at high concentrations (at least 10 mM in the cuvette) while the ManNAc 
concentration was relatively low, so the ManNAc analogues had the best possible 
opportunity to inhibit competitively. 
Due to the insignificant differences in the enzyme activity between the control reaction and 
the reactions in the presence of ManNAc analogues the inhibition constants for the ManNAc 
analogues were not determined for either NmeNANAS or CjeNANAS.  
There was a measured increase in rate of loss of absorbance at 232 nm in the presence of 
2DG. Throughout kinetic testing, the amount of PEP is measured continuously by the use of 
UV spectrophotometry. The reason for the increased rate of PEP loss in the presence of 2DG 
is not clear. It is conceivable that 2DG encourages the loss of PEP via activation of the 
enzyme, or may be acting as a slow alternative substrate of the enzyme. 
3.5 Product analogue 
3.5.1 NANA the natural product 
NANA is the natural product synthesised by the enzyme NANAS. As explained in the 
introduction chapter, NANA is a monosaccharide with a nine carbon backbone which has an 
N-acetyl functional group at the C5 position. The enzyme, NANAS synthesises and releases 
the product in its open ring form (Figure 3.13). Similarly to ManNAc, the released NANA is in 
equilibrium between an open ring and the closed ring structure (Figure 3.14). The 
equilibrium lies to the cyclic form.  
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Figure 3.12 NANA, open ring form. 
 
 
Figure 3.13 Cyclisation of NANA. 
3.5.2 NANA analogue 
Only one product analogue was tested on NANAS, this being the reduced form of NANA 
(rNANA). Another simple analogue, the difference between rNANA and NANA is that the 
carbonyl group is reduced to a hydroxyl group, which prevents cyclisation (Figure 3.14). 
rNANA used in this study was synthesised and provided by Andrew Watson using a method 
outlined in a previous study.66 rNANA used in the kinetic study is in a racemic mixture 
containing two stereoisomers in a 50:50 ratio. 
 
Figure 3.14 NANA analogue, rNANA 
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This analogue was expected to inhibit the enzyme by mimicking the structure of NANA, 
binding to the active site of the enzyme and preventing binding of PEP and ManNAc. The 
analogue rNANA was first tested against NmeNANAS to determine whether rNANA could 
inhibit the catalytic activity of the enzyme.  
3.5.3 Kinetic results 
Kinetic assays were performed using NmeNANAS and CjeNANAS as described in the 
materials and methods section in detail. Since rNANA is a structural mimic of the product 
and not the substrates, both PEP and ManNAc were tested against the inhibitor by testing 
the inhibitor in the presence of variable concentrations of PEP, with constant concentrations 
of ManNAc and vice versa. The Ki value for the inhibitor were determined for both 
NmeNANAS and CjeNANAS.  
3.5.3.1 Inhibition of NmeNANAS with rNANA 
Inhibition with respect to PEP 
The inhibition assay of NmeNANAS with rNANA was used to obtain a Ki value of 0.5 ± 0.1 
mM, exhibiting a competitive inhibition profile with respect to PEP (Figure 3.15). This value 
is 25 times greater than the measured KM of PEP for NmeNANAS, and thus a poor inhibitor in 
respect to PEP.  
 
 
 
 
 
Figure 3.15 (A) Raw data and (B) Lineweaver-Burke plot of NmeNANAS Inhibition with rNANA against 
PEP. Kinetic assays were performed using varied concentrations of PEP, a constant concentration of 
2.58 mM ManNAc and were initiated with approximately 15 µg of the enzyme. The kinetic assay was 
repeated with the additional presence of 1.37 mM and 2.74 mM rNANA.  The assay was completed 
at 25 °C in BTP buffer (50 mM) at pH 8. 
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Inhibition with respect to ManNAc 
The second Ki value for rNANA, as an inhibitor of NmeNANAS, was obtained by testing the 
analogue against an increasing concentration of ManNAc instead of PEP. 
The Ki value for rNANA with respect to ManNAc was 3.0 ± 0.3 mM, and exhibited an 
uncompetitive inhibition profile with respect to a limiting concentration of ManNAc (Figure 
3.16). The exhibition of uncompetitive inhibition may be justified as the enzyme is known to 
bind to PEP first in its ordered sequential mechanism.48 The obtained Ki of rNANA with 
respect to ManNAc was approximately two times greater than the measured KM value for 
ManNAc.  
 
 
 
 
Figure 3.16 (A) Raw data and (B) Lineweaver-Burke plot of NmeNANAS Inhibition with rNANA against 
ManNAc. Kinetic assays were performed using varied concentrations of ManNAc, a constant 
concentration of 0.214 mM PEP and were initiated with approximately 15 µg of the enzyme. The 
kinetic assay was repeated with the additional presence of 2.02 mM and 4.04 mM rNANA.  The assay 
was completed at 25 °C in BTP buffer (50 mM) at pH 8. 
 
3.5.3.2 Inhibition of CjeNANAS with rNANA  
Inhibition with respect to PEP 
The inhibition assay of CjeNANAS with rNANA was used to obtain a Ki of 470 ± 60 µM, 
exhibiting competitive inhibition with respect to PEP (Figure 3.17). This value is 
approximately seven times greater than the measured KM of PEP for CjeNANAS. 
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Figure 3.17 (A) Raw data and (B) Lineweaver-Burke plot of CjeNANAS Inhibition with rNANA against 
PEP. Kinetic assays were performed using varied concentrations of PEP, a constant concentration of 
10.70 mM ManNAc and were initiated with approximately 15 µg of the enzyme. The kinetic assay 
was repeated with the additional presence of 0.5 mM and 1.0 mM rNANA.  The assay was completed 
at 25 °C in BTP buffer (50 mM) at pH 8. 
Inhibition with respect to ManNAc 
The second Ki for rNANA, as an inhibitor of CjeNANAS, was obtained by testing the analogue 
against increasing concentrations of ManNAc instead of PEP.  
The Ki value for rNANA with respect to ManNAc was 3.0 ± 0.4 mM, with this inhibitor 
exhibiting an uncompetitive inhibition profile with respect to ManNAc (Figure 3.18). The 
obtained Ki of rNANA with respect to ManNAc was approximately three times larger than 
the measured KM of ManNAc for CjeNANAS.  
 
 
 
 
 
Figure 3.18 (A) Raw data and (B) Lineweaver-Burke plot of CjeNANAS Inhibition with rNANA against 
ManNAc. Kinetic assays were performed using varied concentrations of ManNAc, a constant 
concentration of 0.214 mM PEP and were initiated with approximately 15 µg of the enzyme. The 
kinetic assay was repeated with the additional presence of 2.04 mM and 3.98 mM rNANA.  The assay 
was completed at 25 °C in BTP buffer (50 mM) at pH 8. 
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3.6 Summary of ManNAc and NANA analogue inhibition 
The kinetic constants that were determined for NmeNANAS and CjeNANAS for each of the 
ManNAc analogues and the NANA analogue discussed in this chapter are summarised in 
Table 3.3 and Table 3.4 respectively. 
None of the ManNAc analogues demonstrated any evidence of acting as alternative 
substrates for either NmeNANAS or CjeNANAS. This may indicate the importance of the 
specific stereochemistry of ManNAc for recognition and utilisation by NANAS.  
The only ManNAc analogue that displayed any evidence to suggest it might be an alternative 
substrate for NmeNANAS and CjeNANAS was 2DG. However, the rate of loss of PEP over 
time was extremely low and thus it is not possible to conclude that 2DG is an alternative 
substrate for the NANAS enzyme. Confirmation would require the full characterisation of 
the alternative product formed between 2DG and NANAS. Obtaining sufficient quantities of 
this product will be a challenge, given the extremely low reaction rates. 
rManNAc was the only ManNAc analogue that inhibited both NANAS enzymes with relative 
potency. The Ki values for rManNAc (against ManNAc) with NmeNANAS and CjeNANAS were 
0.32 ± 0.02 mM and 9 ± 2 µM respectively. These values are approximately four times 
smaller than the measured KM of ManNAc for NmeNANAS and 96 times smaller than the 
measured KM of ManNAc for CjeNANAS respectively. rManNAc exhibited competitive 
inhibition with respect to ManNAc for both NANAS enzymes. The observation that rManNAc 
inhibits NANAS while the other ManNAc analogues were poor inhibitors may be explained 
by rManNAc lacking the ability to form a cyclic structure. It is particularly noteworthy that 
the enzyme is predicted to use an acyclic form of the substrate and may indeed catalyse the 
opening of the cyclic ManNAc substrate. This may account for the level of inhibition seen 
with rManNAc. 
Ki values were determined for the product analogue, rNANA against PEP and ManNAc for 
both NmeNANAS and CjeNANAS. The Ki values of rNANA against PEP for NmeNANAS and 
CjeNANAS were 0.5 ± 0.1 mM and 470 ± 60 µM respectively. The inhibition of both NANAS 
enzyme with rNANA with respect to PEP exhibited a competitive inhibition. The Ki  values of 
rNANA against ManNAc for NmeNANAS and CjeNANAS were 3.0 ± 0.3 mM and 3.0 ± 0.4 mM 
respectively. The inhibition of both NANAS enzymes by rNANA with respect to ManNAc 
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exhibited an uncompetitive inhibition profile. This observation can be explained by the 
binding order of substrates in the NANAS mechanism. PEP is known to bind to NANAS first 
which subsequently promotes the binding of ManNAc to the active site.30 
Table 3.3 Summary of NANAS inhibition with ManNAc analogues. The displayed ManNAc analogues 
which are capable of cyclisation are depicted as pyranose forms. 
Name structure NmeNANAS Ki CjeNANAS Ki 
Alternative 
substrate for 
NmeNANAS 
Alternative 
substrate for 
CjeNANAS 
rManNAc 
 
0.32 ± 0.02 mM 9 ± 2 µM NA NA 
GluNAc 
 
NA NA No No 
GalNAc 
 
NA NA No No 
ManCl 
 
NA NA No No 
2DG 
 
NA NA Maybe Maybe 
 
Table 3.4 Summary of NANAS inhibition with rNANA 
Name structure 
NmeNANAS Ki 
with respect 
to PEP 
NmeNANAS Ki 
with respect 
to ManNAc 
CjeNANAS Ki 
with respect to 
PEP 
CjeNANAS Ki 
with respect 
to ManNAc 
rNANA 
 
0.5 ± 0.1 mM 3.0 ± 0.3 mM 0.47 ± 0.06 mM 3.0 ± 0.4 mM 
 71 
 
 72 
 
Chapter 4                        
Summary of thesis, discussions and future 
directions 
4.1 Summary of results 
The goal of this research was to investigate and compare the inhibition properties of the 
wild-type NANAS enzymes from the pathogenic organisms N. meningitidis and C. jejuni with 
various substrate and product analogues. Enzymes from these organisms were chosen due 
to their role in allowing the bacteria in which they are expressed to evade the host immune 
system via molecular mimicry.23 Inhibition of these enzymes may aid the development of 
alternative antibiotics against these pathogenic bacteria. 
In order to achieve this goal both wild-type NmeNANAS and CjeNANAS were prepared by 
protein expression and purification techniques. The obtained enzymes were tested against a 
range of substrate analogues to investigate whether substrate analogues were able to act as 
alternative substrates or inhibitors for the enzymes and kinetic parameters were 
determined.  
Both PEP and ManNAc substrate analogues were used in this research. In addition, a 
product analogue was tested.  
4.2 The large steric size of the 3-substituted PEP analogues may affect the 
inhibition of NANAS 
Ki values were determined for the PEP analogues against both NANAS enzymes except for 
SEP and the allylic phosphonate, which were found to be non-inhibitory. 
Me-PEP exhibited the poorest inhibition against NmeNANAS, whereas the strongest 
inhibition was shown by Br-PEP followed by Cl-PEP then F-PEP. Me-PEP and F-PEP were the 
poorest inhibitors against CjeNANAS while the strongest inhibitors were Cl-PEP and Br-PEP.  
Inhibition for both types of NANAS by the 3-substituted halo-PEP (3-halo-PEP) analogues 
showed that the relatively larger substituents on the double bond (Br-PEP and Cl-PEP) were 
associated with stronger inhibition. This finding was unexpected since it is reasonable to 
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assume that the larger substituents of the PEP analogue would bind less well to NANAS due 
to steric hindrance with the residues within the active site. Thus the analogues bearing the 
smallest substituents would have been expected to bind to the active site more readily, 
competitively inhibiting NANAS with respect to PEP. All 3-halo-PEP used in this study are 
predominantly in the (Z)-configuration, so the amino acid residues located within the region 
of this substituent in this position would be expected to unfavourably sterically clash with 
the substituent on C3 of these analogues.  
For NmeNANAS for which the structure is known, the residues that may clash can be 
predicted (Figure 4.1). Residues within 4 – 5 Å of C3 of PEP were examined. 
 
 
 
Figure 4.1 The PEP binding site of NmeNANAS. Residues interacting with PEP are labelled. Mn2+ as a 
pink sphere, PEP as blue with phosphate group shown as orange, and N-acetylmannosaminitol as 
green (rManNAc). The residues coloured red represent the amino acid residues from the TIM barrel 
fold and the cyan spheres represent water molecules (PDB code 1XUZ). 
 
 
From an inspection of the PEP bound structure, it is likely that the backbone amino group of 
Ser-131 (which is found 4.1 Å from C3 of PEP), and the side-chain, amide group of Asn-184 
(which is 4.7 Å from C3 of PEP) may clash with the C3-substituent of PEP analogue if the 
Ser-131 
Asn-184 
PEP 
rManNAc 
Ser-113 
Ser-116 
Lys-129 
Lys-53 Thr-110 
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substituent is large in size. All other surrounding residues are at least 6 Å away and 
therefore less likely to clash. 
The observation in these studies was, however, that the 3-halo-PEP with the larger 
substituents exhibited stronger inhibition. This may suggest that the analogues are 
alternatively positioned within the PEP binding site of active site to natural PEP. This may 
relate to the poor ability of these compounds to act as alternative substrates for these 
enzymes.  
Conversely the fluorine substituent of F-PEP is small, and may mean that this compound is 
likely to occupy the same binding position as that the natural substrate. The observation 
that F-PEP can react with ManNAc, albeit slowly, -supports this analogue binding in a similar 
mode to PEP in the active site. 
However, clashes of the fluoro-substituent against surrounding residues are still possible. 
The size of the substituents may not be the only factor in determining whether an analogue 
can be accommodated as electronic factors may come into play. The fluoro substituent is 
highly electronegative in comparison to the hydrogen it replaces. This is especially 
noteworthy as the proposed mechanism for NANAS involves the nucleophilic attack by C3 of 
PEP on ManNAc. The nucleophilicity of the C3 will be reduced by the presence of fluorine on 
C3. 
4.3 The structural conformation of ManNAc may be important for binding to 
the NANAS active site 
Various ManNAc analogues were tested on both NmeNANAS and CjeNANAS, however 
rManNAc was the only analogue which was found to be an inhibitor of these enzymes. All 
other ManNAc analogues were neither alternative substrates nor effective inhibitors. This 
may indicate the importance of the specific stereochemistry of ManNAc for binding and 
utilisation by NANAS. 
The ManNAc binding site of NmeNANAS was observed in the crystal structure 1XUZ (Figure 
4.2). rManNAc was bound with the active site along with PEP, revealing the likely binding 
site of the acyclic aldehyde form of ManNAc. The hydroxyl groups and amino acetyl 
functionality of ManNAc interact with surrounding residues in the binding site. The C3 
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hydroxyl group interacts with both Asp-246 and Gln-55, the C5 hydroxyl group interacts with 
both Asp-246 and Asn-74, and the C6 hydroxyl group interacts with Asn-74. Arg’-314 
(extending into the active site from the other chain of the protein) interacts with the acetyl 
functionality of the N-acetyl group of ManNAc, while the amino functionality of N-acetyl 
group interacts with Tyr-186.  
 
Figure 4.2 The ManNAc binding site of NmeNANAS. Residues interacting with rManNAc are labelled. 
Mn2+ as a pink sphere, PEP as blue with phosphate group shown as orange, and N-
acetylmannosaminitol as green (rManNAc). The residues coloured red represent the amino acid 
residues from the TIM barrel fold, Arg-314’ contributed by the other monomer is coloured as grey 
and the cyan spheres represent water molecules (PDB code 1XUZ). 
 
Arg’-314 assists in the binding of ManNAc and its positioning within the active site so that 
the reactive aldehyde of ManNAc is close to the C3 of PEP to support nucleophilic attack in 
the first step of the reaction.30 Arg-314 has been shown to be of importance by 
mutagenesis.30 Tyr-186 may also aid in this process, interacting with the amino group at the 
C2 position of ManNAc via a hydrogen bond. 
The interaction between Tyr-186 and the amino functionality of the N-acetyl group may 
suggest that this residue is also important for ManNAc binding and catalytic reaction with 
PEP. This may relate to the poor inhibition of the ManNAc analogues and their inability to 
act as alternative substrates, as these compounds all have the N-acetyl group altered in 
some way.  
Tyr-186 
Asp-246 
Asn-74 
Gln-55 
Arg’- 314 
PEP 
rManNAc 
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The different configuration of the hydroxyl group at C4 for GalNAc may have little 
significance in interrupting the binding to NANAS as there appears to be no significant 
interactions between this hydroxyl group and the protein. It is therefore surprising that this 
compound is not observed to be an inhibitor or substrate. 
4.4 Cyclisation of ManNAc analogues and may interrupt the binding of the 
NANAS active site  
The relatively strong inhibition by rManNAc may be explained by the inability of rManNAc to 
form a cyclic structure due to the lack of an aldehyde group. NANAS is predicted to utilise an 
acyclic form of the substrate ManNAc, in order to react with PEP to form NANA. Given only 
a small proportion of the ManNAc found in solution will be in the acyclic form, rManNAc will 
compete with relative advantage to the other analogues tested in these studies. 
The same reasoning can also be applied to the product analogue rNANA inhibition against 
NmeNANAS and CjeNANAS. rNANA (analogue of the product NANA) will be present as an 
acyclic structure, although lactonisation of this compound is possible.  
The large KM of ManNAc for NANAS enzyme could also be explained by the cyclisation of 
ManNAc. The enzyme NANAS may catalyse the opening of the cyclic ManNAc substrate.  
4.5 Future directions 
4.5.1 Is 2DG really an alternative substrate for NANAS? 
2DG demonstrated evidence suggesting that may be an alternative substrate for 
NmeNANAS and CjeNANAS, however the rate of loss of PEP over time was extremely low 
and thus it is not possible to conclude that 2DG is an alternative substrate for the NANAS 
enzyme from these studies. In order to confirm this full characterisation of the alternative 
product formed between 2DG and NANAS is required. Obtaining sufficient quantities of this 
will be a challenge, given the extremely low reaction rates. 
4.5.2 Why does Me-PEP exhibit poor inhibition relative to Br-PEP? 
The inhibition with the 3-substituted PEP analogues suggest that those that bear a large 
substituent may be bound in an alternative position to natural substrate PEP. Crystal 
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structures of these inhibitors in complex with the enzymes may help to ascertain how they 
are achieving their inhibition and rationalise their relative potency. 
Me-PEP exhibited poorer inhibition in comparison to the 3-halo-PEP analogues which have 
an electronegative substituent at the C3 position. The electronegative substituents may 
allow stronger binding to the PEP binding site due to the formation of hydrogen bonding 
interactions to the neighbouring amino acid residue. Structures of these compounds in 
complex with these inhibitors may assist in understanding their potency. 
4.5.3 Mutagenic study of residues within the active site of NANAS 
Potential site directed mutagenesis of amino acid residues, which interact with PEP and 
ManNAc, needs to be performed.  
The importance of amino acid residues within the active site, which interact with ManNAc 
could be investigated by mutating the residues. The mutated NANAS will then be 
characterised with the substrates to observe any significant changes in substrate binding. 
For example Tyr-186 could be mutated to Phe-186 to probe the importance of N-acetyl 
group–Tyr-186 interaction. The importance of other residues which interact with the 
hydroxyl groups of ManNAc could be investigated by mutating Gln-55, Asp-246 and Asn-74 
into Met-55, Leu-246 and Leu-74 respectively.  
Steric clashes with the substituents of 3-halo-PEP could be further investigated by mutating 
residues which are suspected to clash into a residue with smaller side-chain. Asn-184 could 
be mutated into Gly-184 however substrate and inhibitor acceptability could be significantly 
affected by this change. The mutation of Ser-131 may not be mutated since the amino 
group of the back bone of Ser-131 is likely to clash with 3-halo-PEP.  
4.6 Concluding remarks 
In conclusion, using substrate mimicry is a first step in probing the inhibition of an enzyme. 
These inhibitory studies of NmeNANAS and CjeNANAS have provided further understanding 
of how the enzyme accommodates its substrate and this is potentially a useful step in 
developing inhibitors as leads for alternative antibiotics for theses pathogens.
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Chapter 5                                 
Materials and methods  
5.1 Figures and graphs 
5.1.1 Protein 3-dimensional structures 
Figures of protein structures were created using PyMOL version 1.5, Schrödinger LLC. 
5.1.2 Graphing Kinetic Data 
Kinetic constants of enzymes and inhibitors were determined and the data were shown as 
Michaelis Menten constant graphs and double reciprocal graphs (Lineweaver-Burk plot 
graphs) using GRAFIT7 software. 
5.2 General procedures  
5.2.1 Water 
All water used throughout the study was treated with Millipore Milli-Q system for all buffers, 
and solutions.  
5.2.2 pH measurements 
All measurements were made using a Denver Instruments UB-10 Ultra-Basic pH meter, or 
using a Mettler Toledo Seven Compact pH meter with a standard or microprobe. The pH 
meter were calibrated when necessary with the use of standard pH buffer solutions; pH = 4, 
7, and 10. Any solution which required being more acidic, the addition of 1 M HCl or 10 M 
HCl was added to the solution. If the solution required being more basic, the addition of 1 M 
or 10 M NaOH were added to the solution.  
5.2.3 Incubation 
All cell cultures were incubated using Ecotron shaking incubator (Infors HT), shaking at 180 
rpm, incubating at the temperatures of 27 or 37 °C. 
5.2.4 Bacterial cell culture 
Bacterial cells were cultured in a growth media, lysogeny-broth (LB) solution. The LB 
solutions were prepared by the dissolving 20 grams of LB powder into 1 L of Milli-Q water in 
order to prepare LB solution at the concentration of The dissolved LB solution were then 
sterilised by the use of autoclaving and then cooled. The sterilised LB solutions were used as 
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soon as possible to prevent miscellaneous microbes growing significantly into large amounts. 
Antibiotics were added prior to use. 
5.2.5 Bacterial cell preculture  
Preculture of bacterial cells were also prepared into 20 gL-1 LB solution. The growth media 
for bacterial preculture were prepared from dissolving 2 g of LB powder into 100 mL of Milli-
Q water. The prepared solution were sterilised by autoclaving then cooled before used. 
Antibiotics were added prior to use.  
5.3 Cell growth 
5.3.1 Preparation of bacterial preculture 
The transformed E. coli carrying the vector bearing the gene of NANAS were grown in a cell 
growth medium for preculture.  Antibiotics were added to the sterilised LB solution so that 
there was 0.1 mg/mL spectinomycin, 0.1 mg/mL ampicillin, and 0.025 mg/mL 
chloramphenicol as the final concentration in the culture. After inoculation with NmeNANAS, 
the LB solution was incubated at 37 °C in an incubator overnight. 
5.3.2 Full scale growth of bacterial cell and IPTG-induced expression 
2 L of 20 gL-1 LB solution were prepared and sterilised by autoclaving. Antibiotics, ampicillin 
and chloramphenicol, were added so that there is 0.1 mg/mL of ampicillin and 0.025 mg/mL 
chloramphenicol as the final concentration. To each of these LB solutions, 50 mL of the 
prepared preculture is added resulting in the inoculation of the 1 L LB solution. The OD600 of 
the cultures were monitored until reaching the OD of about 0.5-0.6 AU which generally 
takes about 3-4 hours. The cultures were induced by adding IPTG at this point causing the 
final concentration of IPTG to be approximately 0.1 mM. After induction, the LB solution 
was transferred to another shaking another incubator, at the temperature of 27 °C and then 
incubated overnight. The grown cells are harvested by the use of ultra-centrifugation in the 
following day, preferably in the morning in order to prevent the cells from over populating 
and dying. 
5.3.3 Cell harvesting 
The methods involving the harvest of cells from cultures vary depending on the availability 
of the rotor and centrifuge, but typically large cultures of LB solutions with cells cultured 
overnight were centrifuged down into pellets in 1 L bottles at 14,000 g for 30 minutes at the 
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temperature of 4 °C. The cell pellets were re-suspended in buffer used for immobilised 
metal affinity chromatography (IMAC) and then lysed for protein purification. If the cells 
were not being lysed immediately, the cell pellets were stored as -80 °C until required.  
5.4 Protein purification 
5.4.1 Cell lysis  
Cells were lysed by the use of sonication with an Omni-Ruptor 4000 Ultrasonic Homogenizer 
(Omni International). After re-suspension of cell pellet in a buffer solution of 50 mL, the cell 
solution was lysed in a 50 mL beaker chilled by surrounding packed ice. The sonication 
protocol used 70% power burst for 5.5 minutes with 30 seconds of pauses between each 
bursts. Sonication were performed until the lysis had been completed by eye, as the whole 
lysed cell solution exhibit a more thinner and watery consistency. This usually takes about 4-
5 cycles of sonication protocol. All cellular debris was removed by centrifugation at 21,000 g 
for 30 min at 4 °C and collecting the supernatant sample.  
5.4.2 Chromatography systems 
Chromatographic systems were used in order to isolate and purify the protein of interest. All 
chromatography was performed on a Bio-Rad Biologic Duo Flow system. Series of column 
chromatography were used in steps to obtain the purified protein of interest for 
experimentation. IMAC, desalt and size exclusion chromatography (SEC) were used for the 
process of purification. All buffers were filtered through 0.2 μm pore under vacuum and 
degassed prior to use. All samples to be purified were syringe filtered through 0.2 μm pore 
before loaded into a 10 mL or 50 mL Superloop™ (GE Healthcare). All chromatography was 
conducted at 4 °C for protocols taking approximately 1 hour or overnight. 
The eluate from columns was fractionated in 2 mL fractions collected in 96-well plates. 
Elution from the columns was principally monitored at the wavelength 280 nm which is the 
wavelength absorbed by proteins. The wavelength of 260 nm, which is the absorbance of 
DNA, and conductivity were also monitored. Fractions were analysed by gel electrophoresis 
(SDS-PAGE). Fractions containing the enzyme of interest were then pooled and 
concentrated for the next step of purification (or storage) using 10,000 Da molecular weight 
cut-off (MWCO) devices (Vivaspin 2 [GE Healthcare], Vivaspin 500 and Vivaspin 20 [Sartorius 
Stedim Biotech]). 
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5.4.2.1 Immobilised metal affinity chromatography (IMAC) 
The proteins purified contained polyhistidine tags (His-tag) with high affinity for Co2+ ions. 
IMAC were performed in order to isolate proteins with histidine tags from the supernatant, 
using a 5 mL cobalt affinity Talon® column (Clontech). The column was washed with at least 
five column volumes (25 mL) of binding buffer solution for equilibration.  The sample was 
then injected, and the column washed with a further five column volumes (25 mL) of elution 
buffer to remove any unbound proteins.  
Binding buffer: 500 mM NaCl and 50 mM K2HPO4 (pH 8). 
Elution buffer: 500 mM NaCl, 200 mM imidazole, and 50 mM KH2PO4 (pH 8). 
5.4.2.2 Desalting  
Desalting was performed using a 50 mL Bio-Scale Mini Bio-Gel P-6 Desalting Cartridge (Bio-
Rad). The column was used on a Duoflow system with a maximum injection volume of 30 mL. 
The column was equilibrated with two column volumes of buffer (100 mL), after which the 
protein was injected and then eluted with the same buffer. The buffer used for desalting, 
was the same buffer as the binding buffer for IMAC. 
Buffer: 500 mM NaCl and 50 mM K2HPO4 (pH 8).  
5.4.2.3 Size-exclusion chromatography (SEC) 
The protein of interest was purified by SEC as a final stage of purification using a Superdex 
200 26/60 column (GE Healthcare).  The column was equilibrated with one column volume 
(1 L) of the appropriate SEC buffer before the protein was injected, and eluted with one 
column volume (1 L) of the same buffer.  A flow rate of 1 ml/min was used overnight. 
SEC buffer: 30 mM triethanolamine (pH 8). 
5.4.3 Cleavage using TEV protease  
The His-tag attached to the proteins were removed by the use of tobacco etch virus (TEV) 
protease. The protein of interest has a cleavage site which the TEV proteases recognise.  The 
cleavage site sequence used was ENLYFQG, with the protease cleaving between the 
glutamine and glycine residues.  Generally, cleavage was performed after an IMAC column, 
after excess imidazole was removed by desalting.  TEV protease was used at a ratio of 1:100 
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to the substrate protein (by mass, as determined by absorbance). The TEV reaction was 
performed at 4 °C overnight. 
5.5 Purification of TEV protease 
Recombinant TEV protease was similarly purified as the first steps of the purification of 
NANAS.  E. coli BL21 (DE3) cells containing the plasmids pRIL (for rare codon production) and 
pRK793 (encoding TEV protease) were grown in LB containing ampicillin and 
chloramphenicol and induced using IPTG as detailed above.  Cells were lysed by sonication. 
The protein was purified using a single IMAC step with Profinity cartridges, using the buffers 
detailed below.  After purification, the TEV protease in the column bound fractions was 
concentrated to 1 mg/mL, buffer exchanged into storage buffer, and frozen in 1 mL aliquots. 
TEV protease lysis buffer: 10% (v/v) glycerol, 50 mM potassium phosphate (pH 8), 300 mM 
KCl, 25 mM imidazole. 
TEV protease elution buffer: 10% (v/v) glycerol, 50 mM potassium phosphate (pH 8), 300 
mM KCl, 250 mM imidazole. 
5.6 Gel electrophoresis 
SDS-PAGE was performed using either NuPAGE® 10% Bis-Tris 12-well pre-cast gels 
(Invitrogen) or Bolt® 12% Bis-Tris 12-well gels. NuPAGE® gels were run in NuPAGE® MES SDS 
running buffer (Invitrogen). Bolt® gels were run in Bolt® MES SDS running buffer. Samples 
were mixed with protein loading buffer and heated with boiling water prior to analysis with 
gel electrophoresis. Electrophoresis was performed using a XCell SureLock™ Electrophoresis 
Cell (Invitrogen), also at 200 V for 50 min.  
Protein loading buffer (4x) consisted of 41.5 mM Tris-HCl pH 6.8, 40% (v/v) glycerol, 8% 
(w/v) sodium dodecyl sulfate (SDS), 10 mM EDTA, sufficient bromophenol blue to be visible 
and 10 μL of 0.5 M DTT. 
All SDS-PAGE gels were stained in square petri dishes using coomassie brilliant blue R-250, 
for about 15 min before being destained to remove excess dye. Staining and destaining 
times were reduced by heating gel and solution in a microwave oven until almost boiling.  
The molecular weight standard used was Novex® Sharp Pre-Stained Protein Standards 
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(Invitrogen).  Photographs of gels were taken using a white light transilluminator in a 
Molecular Imager® Gel Doc™ XR (Bio-Rad). 
Stain: 0.1% (w/v) coomassie brilliant blue R-250, 10% (v/v) acetic acid and 40% (v/v) 
methanol  
Destain: 10% (v/v) acetic acid and 40% (v/v) methanol  
5.7 Protein concentrations 
Nanodrop ND-1000 spectrophotometer were used to measure the concentration of the 
purified protein. The spectrophotometer measured the absorption at 280 nm. Protein 
concentration was then calculated using the Beer-Lambert Law. The extinction coefficient 
for the protein used for the Beer-Lambert Law calculation was determined from Protparam 
(http://web.expasy.org/protparam/). 
5.8 Enzyme storage 
Purified protein was divided into aliquots in either thin-walled PCR or 0.6 mL micro-
centrifuge tubes in 20 μL to 250 μL aliquots, flash-frozen in liquid nitrogen, and stored at 
−80 °C. All protein samples were rapidly thawed immediately before use and kept on ice.  
5.9 Kinetic characterisations 
5.9.1 Equipment  
All kinetic assays were carried with a Varian Cary 100 UV-visible spectrophotometer, using 
stoppered quartz cuvettes with a pathlength of 1 cm or 0.2 cm.  
The temperature was continuously controlled at 298 K by the use of jacketed multicell 
holder, connected to an external Varian Peltier temperature controller. 
Rates of reaction were measured by calculating a line of least-squares fit of initial rate data 
in the Cary WinUV Kinetic Application (Version 3, Varian). 
5.9.2 Enzyme kinetic assays 
In general, all enzyme kinetics was conducted at 25 °C, in 50 mM BTP buffer at pH of 8, 
initiated with approximately 10 to 15 µg of enzyme.  
Initial velocity data were obtained by the Enzyme activity which were monitored by UV-
Visible spectrophotometry to continuously detect the loss of PEP at 232 nm                             
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(ԑ = 2.8 x 103 M-1cm-1) overtime. The rate (initial velocity) was measured by a least-square fit. 
The continuous decrease in absorbance overtime is due to the enol alkene of PEP consumed 
by the catalytic reaction of NANAS.  
Absorbance was measured through total volumes of 1 mL or 500 µL of sample with the path 
length of 1 cm or 0.2 cm respectively. Depending on the reaction, samples contained a 
range of PEP, ManNAc, and analogue concentrations in quartz cell cuvette. The 
concentrations are specified in the appropriate subsection of this chapter in detail. 
5.9.3 Substrate concentration determination 
The concentrations of the solutions of substrates such as PEP were determined using direct 
kinetic assay at 232 nm. The other substrate ManNAc was determined as the same way 
since the stoichiometry of the NANAS reaction between PEP and ManNAc is 1:1.  
Limiting amounts of substrate to be measured were added to the stoppered quartz cuvette 
while the other substrate was held at excess concentration. The initial absorbance at the 
start of the initiation was subtracted to the final absorbance at the end of the enzymatic 
reaction to get the change of absorbance (ΔAbs). ΔAbs were measured in triplicate. A 
sample containing no substrates was used to measure the change in absorbance due to the 
increase in enzyme (ΔAbsE). The corrected change in absorbance was then calculated as 
ΔAbs - ΔAbsE. The corrected absorbance was then converted to the concentration of the 
limiting substrate using the Beer-Lambert Law with an extinction coefficient of                    
2.8 x 103 M-1cm-1. 
5.9.4 Modelling of Kinetic data 
KM and kcat values were determined by holding the concentration of one substrate constant 
and varying the concentration of the other. The exact substrate concentrations used differ 
in each assay and stated in the appropriate subsection of this chapter. The values were then 
non-linearly fitted to the Michaelis-Menten equation using Grafit5 (Erathicus Software). The 
double reciprocal plots shown in the figures were not used to fit the data and are provided 
simply for illustration.  
Ki values were obtained by performing experimental inhibition assays at different 
concentrations of the substrates and inhibitor. Each substrate were at limiting 
concentrations depending on the inhibitor, whether it is a PEP analogue or ManNAc 
 86 
 
analogue. The exact substrate and inhibitor concentrations used differ in each assay and 
stated in the appropriate subsection of this chapter. The data were modelled using Grafit5 
fitting into a competitive model or a mixed inhibition model.   
5.9.5 Kinetic conditions in chapter 2  
5.9.5.1 Michaelis-Menten conditions for the determination of PEP KM values 
5.9.5.1.1 NmeNANAS 
The PEP KM values were determined for NmeNANAS under the following conditions: 
constant concentrations of 1.2 mM ManNAc, and varying concentrations of PEP (0.0036 mM, 
0.0073 mM, 0.015 mM, 0.022 mM, 0.029 mM, 0.0729 mM, 0.11 mM, and 0.15 mM) 
initiated with approximately 10 µg of NmeNANAS.  
5.9.5.1.2 CjeNANAS 
The PEP KM values were determined for CjeNANAS under the following conditions: constant 
concentrations of 11.3 mM ManNAc, and increasing concentrations of PEP (0.011 mM, 
0.021 mM, 0.032 mM, 0.053 mM, 0.074 mM, 0.11 mM, 0.13 mM, 0.16 mM, 0.21 mM, 0.27 
mM, 0.32 mM, and 0.37 mM) initiated with approximately 15 µg of CjeNANAS. 
5.9.5.2 Inhibition assay conditions  
5.9.5.2.1 Enzyme kinetics for NmeNANAS with SEP 
The kinetic assay was initiated with approximately 10 µg of NmeNANAS under the following 
conditions: constant concentration of 1.1 mM ManNAc and constant concentrations of 0.11 
mM PEP to determine the control rate. The kinetic assay was repeated with the conditions 
above with the additional presence of 1.03 mM SEP. The enzyme with the presence of SEP 
showed no significant loss of activity than the control. 
5.9.5.2.2 Enzyme kinetics for CjeNANAS with SEP 
The kinetic assay was initiated with approximately 15 µg of CjeNANAS under the following 
conditions: constant concentration of 111.55 mM ManNAc and constant concentrations of 
0.07 mM PEP to obtain the control. The kinetic assay was repeated with the conditions 
above with the additional presence of 1.0 mM SEP. The enzyme with the presence of SEP 
showed no significant loss of activity than the control. 
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5.9.5.2.3 Enzyme kinetics for NmeNANAS with allylic phosphonate 
The kinetic assay was initiated with approximately 10 µg of NmeNANAS under the following 
conditions: constant concentration of 2.12 mM ManNAc and constant concentrations of 
0.11 mM PEP to determine the control. The kinetic assay was repeated with the conditions 
above with the additional presence of 0.8 mM allylic phosphonate. The enzyme with the 
presence of SEP showed no significant loss of activity than with the control, absence of 
allylic phosphonate. 
5.9.5.2.4 Enzyme kinetics for CjeNANAS with allylic phosphonate 
The kinetic assay was initiated with approximately 15 µg of CjeNANAS under the following 
conditions: constant concentration of 111.55 mM ManNAc and constant concentrations of 
0.07 mM PEP to determine the control. The kinetic assay was repeated with the conditions 
above with the additional presence of 1.0 mM allylic phosphonate. The enzyme with the 
presence of SEP showed no significant loss of activity than with the control, absence of 
allylic phosphonate. 
5.9.5.2.5 Enzyme kinetics for NmeNANAS with F-PEP 
The Ki value for NmeNANAS with F-PEP were determined under the following conditions: 
constant concentrations of 10.82 mM ManNAc, and increasing concentrations of PEP (0.10 
mM, 0.21 mM, 0.62 mM, and 1.04 mM) initiated with approximately 10 µg of NmeNANAS. 
The kinetic assay was repeated with the above conditions with the additional presence of 
0.410 mM, and 0.822 mM F-PEP. 
5.9.5.2.6 Enzyme kinetics for CjeNANAS with F-PEP 
The Ki value for CjeNANAS with F-PEP were determined under the following conditions: constant 
concentrations of 10.05 mM ManNAc, and increasing concentrations of PEP (0.07  mM, 0.11 
mM, 0.22 mM, and 0.44 mM) initiated with approximately 15 µg of NmeNANAS. The kinetic 
assay was repeated with the above conditions with the additional presence of 0.32 mM, and 
0.065 mM F-PEP.  
5.9.5.2.7 Enzyme kinetics for NmeNANAS with Cl-PEP 
The Ki value for NmeNANAS with Cl-PEP were determined under the following conditions: 
constant concentrations of 10.9 mM ManNAc, and increasing concentrations of PEP (0.11 
mM, 0.21 mM, 0.63 mM, and 1.06 mM) initiated with approximately 10 µg of NmeNANAS. 
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The kinetic assay was repeated with the above conditions with the additional presence of 
0.21 mM, and 0.42 mM Cl-PEP. 
5.9.5.2.8 Enzyme kinetics for CjeNANAS with Cl-PEP 
The Ki value for CjeNANAS with Cl-PEP were determined under the following conditions: constant 
concentrations of 11.15 mM ManNAc, and increasing concentrations of PEP (0.11  mM, 0.21 
mM, 0.43 mM, and 0.64 mM) initiated with approximately 15 µg of CjeNANAS. The kinetic 
assay was repeated with the above conditions with the additional presence of 0.01 mM, and 
0.03 mM Cl-PEP.  
5.9.5.2.9 Enzyme kinetics for NmeNANAS with Br-PEP 
The Ki value for NmeNANAS with Br-PEP were determined under the following conditions: 
constant concentrations of 20.2 mM ManNAc, and increasing concentrations of PEP (0.07 
mM, 0.11 mM, 0.33 mM, and 0.44 mM) initiated with approximately 10 µg of NmeNANAS. 
The kinetic assay was repeated with the above conditions with the additional presence of 
0.39 mM, and 0.75 mM Br-PEP.  
5.9.5.2.10 Enzyme kinetics for CjeNANAS with Br-PEP 
The Ki value for CjeNANAS with Br-PEP were determined under the following conditions: 
constant concentrations of 11.16 mM ManNAc, and increasing concentrations of PEP (0.11  
mM, 0.21 mM, 0.43 mM, and 0.64 mM) initiated with approximately 15 µg of CjeNANAS. 
The kinetic assay was repeated with the above conditions with the additional presence of 
0.01 mM, and 0.03 mM Br-PEP.  
5.9.5.2.11 Enzyme kinetics for NmeNANAS with Me-PEP 
The Ki value for NmeNANAS with Me-PEP were determined under the following conditions: 
constant concentrations of 10.9 mM ManNAc, and increasing concentrations of PEP (0.09 
mM, 0.18 mM, 0.54 mM, and 0.89 mM) initiated with approximately 10 µg of NmeNANAS. 
The kinetic assay was repeated with the above conditions with the additional presence of 
0.68 mM, and 1.35 mM Me-PEP. 
5.9.5.2.12 Enzyme kinetics for CjeNANAS with Me-PEP 
The Ki value for CjeNANAS with Me-PEP were determined under the following conditions: 
constant concentrations of 10.05 mM ManNAc, and increasing concentrations of PEP (0.07  
mM, 0.11 mM, 0.22 mM, and 0.44 mM) initiated with approximately 15 µg of CjeNANAS. 
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The kinetic assay was repeated with the above conditions with the additional presence of 
0.04 mM, and 0.08 mM Me-PEP.  
5.9.6 Kinetic conditions in chapter 3  
5.9.6.1 Michaelis-Menten conditions for the determination of ManNAc KM 
values 
5.9.6.1.1 NmeNANAS 
The ManNAc KM values were determined for NmeNANAS under the following conditions: 
constant concentrations of 0.19 mM PEP, and varying concentrations of ManNAc (0.29 mM, 
0.43 mM, 0.72 mM, 1.44 mM, 2.88 mM, 5.76 mM, 7.20 mM, 8.64 mM, 10.08 mM, and 13.97 
mM) initiated with approximately 10 µg of NmeNANAS.  
5.9.6.1.2 CjeNANAS 
The ManNAc KM values were determined for CjeNANAS under the following conditions: 
constant concentrations of 0.32 mM PEP, and varying concentrations of ManNAc (0.11 mM, 
0.17 mM, 0.23 mM, 0.34 mM, 0.45 mM, 0.56 mM, 0.68 mM, 1.13 mM, 2.26 mM, 3.38 mM, 
4.51 mM, 5.64 mM, 6.77 mM, 7.90 mM, 9.03 mM, 10.15 mM, and 11.28 mM) initiated with 
approximately 15 µg of CjeNANAS. 
5.9.6.2 Inhibition assay conditions  
5.9.6.2.1 Enzyme kinetics for NmeNANAS with rManNAc 
The Ki value for NmeNANAS with rManNAc were determined under the following 
conditions: constant concentrations of 0.22 mM PEP, and increasing concentrations of 
ManNAc (0.94 mM, 1.89 mM, 4.7 mM, and 9.4 mM) initiated with approximately 10 µg of 
NmeNANAS. The kinetic assay was repeated with the above conditions with the additional 
presence of 1.05 mM, and 2.2 mM rManNAc.  
5.9.6.2.2 Enzyme kinetics for CjeNANAS with rManNAc 
The Ki value for CjeNANAS with rManNAc were determined under the following conditions: 
constant concentrations of 0.29 mM PEP, and increasing concentrations of ManNAc (0.99 
mM, 1.98 mM, 2.97 mM, and 3.96 mM) initiated with approximately 15 µg of CjeNANAS. 
The kinetic assay was repeated with the above conditions with the additional presence of 
0.013 mM, and 0.025 mM rManNAc. 
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5.9.6.2.3 Enzyme kinetics for NmeNANAS and CjeNANAS with other ManNAc 
analogues 
The rest of the ManNAc analogues GluNAc, GalNAc, ManCl, and 2DG were tested with 
NmeNANAS and CjeNANAS. 
All ManNAc analogues, used in this study (with the exception of rManNAc), were purchased 
from Sigma-Aldrich®. The analogue rManNAc was prepared by the reduction of ManNAc 
with sodium borohydride, as described in the experimental chapter.9 
The kinetic assay was initiated with approximately 10 to 15 µg of NmeNANAS and CjeNANAS 
respectively under the following conditions: constant concentration of 0.2 mM and 0.28 mM 
PEP respectively and constant concentration of 0.5 mM ManNAc (for both enzymes) to 
determine the control reaction rate. The assay was repeated with additional presence of 
various 10 mM ManNAc analogues in excess. The enzyme with the presence of other 
ManNAc analogues showed no significant loss of activity than the control. 
5.10 Preparation of rManNAc 
Reduced ManNAc (rManNAc) was synthesised using the method outlined in Gunawan et al.9 
0.21 g of ManNAc (1 mM) was dissolved in 10 mL of water and 0.08 g of sodium borohydride 
(2 mM) added to the solution. The mixture was subsequently stirred at room temperature 
for 2 hours. The resulting solution was neutralised using Dowex® 50WX8 hydrogen form, 
100-200 mesh (Sigma-Aldrich). The solution was then filtered and lyophilised, producing a 
white solid. The product was subsequently refluxed in 50 mL of methanol for 30 min and 
concentrated under reduced pressure. The resultant oily film was re-dissolved in water and 
lyophilised to produce a white solid (0.15 – 0.16 g). Purity of rManNAc was determined 
through 1HNMR to be above 99 %. 
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